CA2389773A1 - Activators of soluble guanylate cyclase - Google Patents

Activators of soluble guanylate cyclase Download PDF

Info

Publication number
CA2389773A1
CA2389773A1 CA002389773A CA2389773A CA2389773A1 CA 2389773 A1 CA2389773 A1 CA 2389773A1 CA 002389773 A CA002389773 A CA 002389773A CA 2389773 A CA2389773 A CA 2389773A CA 2389773 A1 CA2389773 A1 CA 2389773A1
Authority
CA
Canada
Prior art keywords
dimethylamino
propyl
phenyl
chloro
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002389773A
Other languages
French (fr)
Inventor
Robert Glen
Karen Reynolds
David Selwood
Grant Wishart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
University College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9926286.7A external-priority patent/GB9926286D0/en
Application filed by University College London filed Critical University College London
Publication of CA2389773A1 publication Critical patent/CA2389773A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/37—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/40—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/62—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/50—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/82—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/26—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C275/36—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with at least one of the oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. N-aryloxyphenylureas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/38—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
    • C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
    • C07C2603/50—Pyrenes; Hydrogenated pyrenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pyridine Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the activation of soluble guanylate cyclase, wherein: R1 and R2 are the same or different and each represent a C1-C6 alkyl group, or R1 and R2 together form a C3-C6 alkylene group; Z is a C1-C4 alkylene group; P is a direct bond or a moiety -X-, -Y-, -W-, -XY-, -YW- or -XYW-, wherein; W is -O-, -S-, or -NR3, wherein R3 is hydrogen or C1-C6 alkyl; Y is a moiety -U-V- wherein V is a direct bond or a C1-C6 alkylene group and U is -CS-, -CO-, -S(O)2- or -C(=NR)- wherein R is hydrogen, hydroxy or C1-C6 alkyl; X is -O- or -NR6- wherein R6 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl or heteroaryl; and R4 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, a group -R-A wherein R is -(C1-C6 alkyl)-, -(C2-C6 alkenyl)- or -(C2-C6 alkynyl)- and A is aryl, heteroaryl, carbocyclyl or heterocyclyl, or R4 is a group -COR", -CO2R", -S(O)2R" or -CONR'R" wherein R' is hydrogen, C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl and R" is aryl, heteroaryl, carbocyclyl or heterocyclyl.

Description

ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE
This invention relates to activators of soluble guanylate cyclase (sGC), to their preparation and to their use.
Soluble guanylate cyclase is responsible for the enzymatic conversion of S guanosine-5'-triphosphate (GTP) to cyclic guanosine-3',5'-monophosphate (cGMP) The enzyme is stimulated by NO binding to the enzyme.
sGC is responsible for numerous physiological processes including vascular and non-vascular smooth muscle relaxation, peripheral and central neurotransmission, platelet reactivity and phototransduction (Hobbs A.J., TiPS, December 1997, Vol 18, p.484). Activators of sGC can therefore be expected to have valuable therapeutic properties.
As explained above, NO is known as an activator of sGC. However, this compound has a number of different physiological effects and its use in activating sGC therefore suffers from a myriad of side effects. There is therefore a need for selective activators of sGC.
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole (YC-1) is a known NO
independent activator of sGC (Hobbs, A.J., TiPS, December 1997, Vol 18, p.484).
However, the activation achieved is not high.
Accordingly, the present invention provides the use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the activation of soluble guanylate cyclase (~

wherein:
- Rl and RZ are the same or different and each represent a C,-C6 alkyl group, or R, and RZ together form a C3-C6 alkylene group;
- Z is a C,-C4 alkylene group;
- P is a direct bond or a moiety -X-, -Y-, -W-, -XY-, -YW- or -XYW-, wherein:
- W is -O-, -S-, or -NR3, wherein R3 is hydrogen or C,-C6 alkyl;
Y is a moiety -U-V- wherein V is a direct bond or a C,-C6 alkylene group and U is -CS-, -CO-, -S(O)2- or -C(=NR)-wherein R is hydrogen, hydroxy or C1-C6 alkyl;
X is -O- or -NR6- wherein R6 is hydrogen, C,-C6 alkyl, CZ-C6 alkenyl, CZ-C6 alkynyl, aryl or heteroaryl; and R4 is C,-C6 alkyl, CZ-C6 alkenyl, Cz-C6 alkynyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, a group -R-A wherein R is -(C,-C6 alkyl)-, -(CZ-C6 alkenyl)- or -(Cz-C6 alkynyl)- and A is aryl, heteroaryl, carbocycyl or heterocyclyl, or R4 is a group -COR~~, -COzR~~, -S(O)ZR°
or -CONR~R~~ wherein R~ is hydrogen, C,-C6 alkyl, Cz-C6 alkenyl or Cz-C~ alkynyl and R~~ is is aryl, heteroaryl, carbocyclyl or heterocyclyl.
In the moiety P, the moiety -X-, when present, is attached to R4 and the moiety W, when present, is attached to Z. In the moiety Y, the moiety V is attached to W or, if W is not present, to Z, and the moiety U is attached to X or, if X
is not present, to R4.
As used herein, a C,-C6 alkyl group or moiety is a linear or branched alkyl group or moiety. Suitable alkyl groups and moieties include CI-C4 alkyl groups and moieties, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl and t-butyl.
Methyl, ethyl, n-propyl and t-butyl are preferred.
A C,-C6 alkyl group or moiety can be substituted or unsubstituted at any position. Typically, it is unsubstituted or carries 1, 2 or 3 substituents.
Suitable substituents include C,-C~ alkyl, C,-C6 alkylthio, C,-C6 alkoxy, C,-C6 haloalkyl, for example -CF3 and -CCl3, C,-C6 haloalkoxy, for example -OCF3 and -OCC13, halogen, hydroxy, cyano, nitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, oxo, -NR~R~~ wherein R~ and R~~ are the same or different and are hydrogen or C,-C6 alkyl, =NR, -COR, -CONR,R, -COZR, -NR,COR, -NR,COZR, -NR,CONR,R, -S(O)zR and -S(O)ZNR,R wherein each R, can be the same or different and represents hydrogen or C,-C6 alkyl and each R can be the same or different and represents C,-C6 alkyl, aryl, heteroaryl, heterocyclyl or carbocyclyl, and -S-(C,-C6 alkyl)-R~~~ and -O-(C,-C6 alkyl)-R~~~ wherein each R~~~ can be the same or different and represents aryl, heteroaryl, heterocyclyl or carbocyclyl.
Further, two substituents on the same atom can, together with the atom to which they are attached, form a carbocyclyl or heterocyclyl group.
Preferred substituents include oxo, halogen, C,-C6 alkyl, aryl, arylthio, aryloxy, heteroaryl, heteroarylthio, heteroaryloxy and -NR~R~~, =N-R, -CONHR
and -NHCOZR wherein R, R~ and R~~ are as defined above. Further, two preferred substituents on the same carbon atom may, together with the atom to which they are attached, form a carbocyclyl group, preferably a C3-C6 cycloalkyl group.
More preferred substituents are oxo, halogen, for example chlorine and fluorine, C~-C4 alkyl, for example methyl, ethyl or t-butyl, aryl, for example phenyl, -CONH-aryl, for example -CONH-phenyl, =N-aryl, for example =N-phenyl, -NH-COZ-(C,-C4 alkyl), heteroarylthio, for example pyrimidinethio and -CO-aryl, for example -CO-phenyl. It is also preferred that two substituents on the same carbon atom may, together with the atom to which they are attached, form a C3-C6 cycloalkyl group.
As used herein, a CZ-C6 alkenyl group or moiety is a linear or branched alkenyl group or moiety. Suitable alkenyl groups and moieties include CZ-C4 alkenyl groups and moieties such as ethenyl, propenyl and butenyl groups and moieties.
Ethenyl and propenyl are preferred. A Cz-C6 alkenyl group or moiety may be substituted or unsubstituted at any position.
A CZ-C~ alkenyl group is typically unsubstituted or carries 1, 2, 3 or 4 substituents. Preferably, it carries at least two substituents. Suitable substituents include oxo, C,-C6 alkyl, C,-C6 alkylthio, C,-C6 alkoxy, C~-C6 haloalkyl, for example -CF3 and -CC13, C,-C6 haloalkoxy, for example -OCF3 and -OCC13, halogen, hydroxy, cyano, vitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, -NR~R~~ wherein R~ and R~~ are the same or different and are hydrogen or C,-C6 alkyl, =N-R, -COR, -CONR,R, -COZR, -NR,COR, -NR,COzR, -NR,CONR,R, -S(O)ZR and -S(O)ZNR,R wherein each R, can be the same or different and represents hydrogen or C1-C6 alkyl and each R can be the same or different and represents C,-C6 alkyl, aryl, heteroaryl, heterocyclyl or carbocyclyl, and -S-(C,-C6 alkyl)-R~~~ and -O-(C,-C6 alkyl)-R~~~ wherein each R~~~ can be the same or different and represents aryl, heteroaryl, heterocyclyl or carbocyclyl.
Further, two substituents on the same atom can, together with the atom to which they are attached, S form a carbocyclyl or heterocyclyl group.
Preferred substituents include oxo, halogen, C,-C6 alkyl, aryl, arylthio, aryloxy, heteroaryl, heteroarylthio, heteroaryloxy and -NR~R~~, =N-R, -CONHR
and -NHCOZR wherein R, R~ and R~~ are as defined above. Further, two preferred substituents on the same carbon atom may, together with the atom to which they are attached, form a carbocyclyl group, preferably a C3-C$ cycloalkyl group.
More preferred substituents are halogen, for example chlorine and fluorine, C,-C4 alkyl, for example methyl, ethyl or t-butyl, aryl, for example phenyl, heteroaryl, for example furanyl, -CONH-aryl, for example -CONH-phenyl, -NH-COZ-(C,-C4 alkyl), -NH-CO-(C,-C4 allcyl), -NH-CO-aryl, for example -NH-CO-phenyl, heteroarylthio, for example pyrimidinethio and -CO-aryl, for example -CO-phenyl. It is also preferred that two substituents on the same carbon atom may, together with the atom to which they are attached, form a C3-C8 cycloalkyl group.
A CZ-C6 alkynyl group or moiety is typically an ethynyl, propynyl or butynyl group or moiety. It may be substituted or unsubstituted at any position.
Typically, it is unsubstituted or carnes 1 or 2 substituents. Suitable substituents include C,-C6 alkyl, C,-C6 alkylthio, C,-C6 alkoxy, C,-C6 haloalkyl, for example -CF3 and -CCl3, C,-C6 haloalkoxy, for example -OCF3 and -OCC13, halogen, hydroxy, cyano, nitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, -NR~R~~ wherein R~ and R~~ are the same or different and 'are hydrogen or C,-C6 alkyl, -COR, -CONR,R, -COZR, -NR,COR, -NR,COZR, -NR,CONR,R, -S(O)ZR and -S(O)ZNR,R wherein each R, can be the same or different and represents hydrogen or C,-C6 alkyl and each R can be the same or different and represents C,-C6 alkyl, aryl, heteroaryl, heterocyclyl or carbocyclyl, and -S-(C,-C6 alkyl)-R~~~ and -O-(C,-C6 alkyl)-R~~~ wherein each R~~~ can be the same or different and represents aryl, heteroaryl, heterocyclyl or carbocyclyl. Further, two substituents on the same atom can, together with the atom to which they are attached, form a carbocyclyl or heterocyclyl group.
Preferred substituents include halogen, C,-C6 alkyl, aryl, arylthio, aryloxy, heteroaryl, heteroarylthio, heteroaryloxy and -CONHR and -NHCOzR wherein R is as defined above. Further, two preferred substituents on the same carbon atom may, together with the atom to which they are attached, form a carbocyclyl group, preferably a C3-C6 cycloalkyl group.
More preferred substituents are halogen, for example chlorine and fluorine, C,-C4 alkyl, for example methyl, ethyl or t-butyl, aryl, for example phenyl, -CONH-aryl, for example -CONH-phenyl, -NFi-COZ-(C,-C4 alkyl), heteroarylthio, for example pyrimidinethio and -CO-aryl, for example -CO-phenyl. It is also preferred that two substituents on the same carbon atom may, together with the atom to which they are attached, form a C3-C6 cycloalkyl group.
A C,-C6 alkoxy group is typically a said C~-C6 alkyl group attached to an 1 S oxygen atom. A C,-C6 alkylthio group is typically a said C,-C6 alkyl group attached to a sulphur atom.
As used herein, a said alkylene group is a divalent alkyl moiety. It may be unsubstituted or substituted at any position. Typically, it is unsubstituted or monosubstituted. Suitable substituents include halogen, for example chlorine and flourine, hydroxy, C,-C4 alkyl such as methyl and ethyl, C,-C4 alkoxy, for example methoxy, C~-C4 haloalkyl, for example -CF3 and -CC13 and C,-C4 haloalkoxy, for example -OCF3 and -OCCl3. These substituents are typically themselves unsubstituted.
A halogen is typically chlorine, fluorine, bromine or iodine. It is preferably chlorine.
A haloalkyl or haloalkoxy group is typically a said alkyl or alkoxy group substituted by one or more said halogen atoms. Typically, it is substituted by l, 2 or 3 said halogen atoms. Preferred haloalkyl and haloalkoxy groups include perhaloalkyl and perhaloalkoxy groups such as -CX3 and -OCX3 wherein X is a said halogen atom. Particularly preferred haloalkyl groups are CF3 and CC13.
Particularly preferred haloalkoxy groups are -OCF3 and -OCCl3.
As used herein, an aryl group or moiety is typically a C6-CZO aryl group or moiety. Suitable such aryl groups and moieties include phenyl, naphthyl and pyrenyl. Phenyl and pyrenyl are preferred.
An aryl group or moiety may be substituted or unsubstituted at any position.
Typically, it is unsubstituted or carnes 1, 2, 3 or 4 substituents. Suitable substituents include C,-C6 alkyl, C,-C6 alkylthio, C,-C6 alkoxy, C,-C6 haloalkyl, for example -CF3 and -CCl3, C,-C6 haloalkoxy, for example -OCF3 and -OCC13, halogen, cyano, hydroxy, vitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, -NR~R~~ wherein R~ and R~~ are the same or different and are hydrogen or C,-C6 alkyl, -COR, -CONR,R, -COzR, -NR,COR, -NR,COZR, -NR,CONR, R, -S(O)zR and -S(O)ZNR,R wherein each R, can be the same or different and represents hydrogen or C,-C~ alkyl and each R can be the same or different and represents C,-C6 alkyl, aryl, heteroaryl, heterocyclyl or carbocyclyl, and -S-(C,-C6 alkyl)-R~~~ and -O-(C1-C6 alkyl)-R~~~ wherein each R~~~ can be the same or different and represents aryl, heteroaryl, heterocyclyl or carbocyclyl.
Preferred substituents include C,-C6 alkyl, for example methyl and ethyl, C1-C6 alkoxy, for example methoxy, C,-C6 alkylthio, for example methylthio, C,-haloalkyl, for example -CF3 and -CC13, C,-C6 haloalkoxy, for example -OCF3 and -OCCl3, halogen, for example chlorine and fluorine, vitro, cyano, aryl, for example phenyl, aryloxy, for example phenyloxy, arylthio, for example phenylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, -NR~R~~ wherein R~ and R~~ are the same or different and are hydrogen or C,-C~ alkyl, -CONH-(C,-C6 alkyl), -NHCONH-R wherein R is aryl, for example phenyl, or heteroaryl, -S(O)ZNHR~
wherein R~ is aryl, for example phenyl, or heteroaryl, -S-(C1-C6 alkyl)-R~~
wherein R~~
is aryl, for example phenyl, or heteroaryl and -COR~~~ wherein R~~~ is heterocycyl, heteroaryl or aryl.
Particularly preferred substituents are phenyl, in particular 4-phenyl, phenoxy, in particular 2-phenoxy, phenylthio, halogen, -CF3, -CC13, vitro, cyano, -OCF3, -OCC13, C,-C4 alkyl, C,-C4 alkoxy, C,-C4 alkylthio, -CONH-(C,-C4 alkyl), -CO-phenyl, -S(O)ZNH-phenyl, -S-(C~-C4 alkyl)-phenyl, -S-(C,-C4 alkyl)-pyrazole, -S-(C,-C4 alkyl)-pyrimidine, -(C,-C4 alkyl)-NH-COz-(C,-C4 alkyl), thiazole, -COR
wherein R is benzothiophenyl or ~i-carbolinyl and -NH-(CHZ)nNR'R" wherein n is from 2~to 4 and R' and R" are the same or different and are C,-C4 alkyl.
An aryl group or moiety may be fused to a further said aryl group or to a S carbocyclic, heterocyclic or heteroaryl group. For example, an aryl group may be fused to a pyridine ring to form a quinoline or isoquinoline group, or to a furan ring.
It may also, for example, be fused to a cyclopropyl or cyclohexyl group or to a tetrahydrofuryl group, a 1,4-dioxolane group or a pyrimidone ring, for example a 4-pyrimidone ring.
As used herein, a carbocyclic group or moiety is a non-aromatic, saturated or unsaturated carbocyclic group or moiety. Typically, it has from 3 to 10, for example from 3 to 8, carbon atoms. Preferably, it has from 3 to 8, for example 3 to 6, carbon atoms. Examples of suitable carbocyclic groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclopetadienyl, cyclohexyl, cyclohexenyl and cyclooctanyl groups. Preferred carbocyclic groups include cyclohexyl, cyclooctanyl and cyclohexenyl groups.
A carbocyclic group or moiety may be unsubstituted or substituted at any position. Typically, it carries up to 3 substituents. Suitable substituents include oxo, C,-C6 alkyl, C,-C6 alkylthio, C,-C6 alkoxy, C,-C6 haloalkyl, for example -CF3 and -CC13, C,-C6 haloalkoxy, for example -OCF3 and -OCCl3, halogen, hydroxy, cyano, nitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, -NR'R" wherein R' and R" are the same or different and are hydrogen or C,-C6 alkyl, =NR, -COR, -CONR,R, -COZR, -NR,COR, -NR,COZR, , -NR,CONR,R, -S(O)ZR and -S(O)ZNR,R wherein each R, can be the same or different and represents hydrogen or C,-C6 alkyl and each R can be the same or different and represents C,-C6 alkyl, aryl, heteroaryl, heterocyclyl or carbocyclyl, and -S-(C,-C6 alkyl)-R"' and -O-(C,-C6 alkyl)-R"' wherein each R"' can be the same or different and represents aryl, heteroaryl, heterocyclyl or carbocyclyl.
Further, two substituents on the same atom can, together with the atom to which they are attached, form a carbocyclyl or heterocyclyl group.

_g_ Preferred substituents include oxo, C,-C6 alkyl, for example methyl and ethyl, C,-C6 alkoxy, for example methoxy, C,-C6 alkylthio, for example methylthio, C,-haloalkyl, for example -CF3 and -CCl3, C,-C6 haloalkoxy, for example -OCF3 and -OCC13, halogen, for example chlorine and fluorine, vitro, cyano, aryl, for example S phenyl, aryloxy, for example phenyloxy, arylthio, for example phenythio, heteroaryl, heteroarylthio, heterocyclyl, -CONH-(C,-C6 alkyl), -NHCONH-R wherein R is aryl, for example phenyl, or heteroaryl, =NR~ wherein R~ is aryl, for example phenyl, or heteroaryl, -S(O)ZNHR~~ wherein R~~ is aryl, for example phenyl, or heteroaryl, -S-(C,-C6 alkyl)-R~~~ wherein R~~~ is aryl, for example phenyl, or heteroaryl, and -COR~~~~ wherein R~~~~ is heterocyclyl, heteroaryl or aryl.
Particularly preferred substituents are oxo, =N-aryl, for example =N-phenyl, aryl, for example phenyl, and -CO-aryl, for example -CO-phenyl.
A carbocyclic group or moiety may be fused to a further carbocyclic group or to an aryl, heteroaryl or heterocyclic group.
A heteroaryl group or moiety is typically a 5- to 10- membered aryl ring containing at least one heteroatom, for example 1, 2 or 3 heteroatoms, selected from O, S and N. Preferably, the heteroaryl group or moiety is a 5- or 6- membered ring.
Suitable heteroaryl groups and moieties include pyridyl, pyranyl, furanyl, thienyl, pyrazolidinyl, pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, furazanyl, triazolyl and thiadiazolyl groups. Pyridyl, pyrrolyl, thienyl, thiazolyl, furanyl, pyrazinyl and 1, 2, 3-thiadiazolyl groups are preferred.
A heteroaryl group or moiety may be unsubstituted or substituted at any position. Typically, it is unsubstituted or carries up to three substituents.
Suitable substituents include C~-C6 alkyl, C1-C6 alkylthio, C,-C6 alkoxy, C1-C6 haloalkyl, for example -CF3 and -CC13, C,-C6 haloalkoxy, for example -OCF3 and -OCC13, halogen, hydroxy, cyano, vitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, -NR~R~~ wherein R~ and R~~ are the same or different and are hydrogen or C~-C6 alkyl, -COR, -CONR,R, -C02R, -NR,COR, -NR,COzR, -NR,CONR,R, -S(O)zR and -S(O)ZNR,R wherein each R, can be the same or different and represents hydrogen or C,-C6 alkyl and each R can be the same or different and represents C,-C6 alkyl, aryl, heteroaryl, heterocyclyl or carbocyclyl, and -S-(C,-C6 alkyl)-R~~~ and -O-(C,-C6 alkyl)-R~~~ wherein each R~~~ can be the same or different and represents aryl, heteroaryl, heterocyclyl or carbocyclyl.
Preferred substituents include C,-C6 alkyl, for example methyl and ethyl;
C,-C6 alkoxy, for example methoxy, C,-C6 alkylthio, for example methylthio, C,-haloalkyl, for example -CF3 and -CCl3, C,-C6 haloalkoxy, for example -OCF3 and -OCC13, halogen, for example chlorine, cyano, nitro, aryl, for example phenyl, aryloxy, for example phenoxy, arylthio, for example phenylthio and -O-(C,-C6 alkyl)-R, -S-(C,-C6 alkyl)-R, -S-(C,-C6 alkyl)-CONH-R, -CO-R and -CO-NH-R, wherein R is an aryl group, for example a phenyl group.
Particularly preferred substituents include phenyl, halogen, for example chlorine, C,-C4 alkyl, for example methyl, -CF3, -CC13, -OCF3, -OCC13, phenylthio, phenoxy, -S-(C,-C4 alkyl)-CONH-phenyl, -S-(C,-C4 alkyl)-phenyl, -O-(C,-C4 alkyl-phenyl, -CO-phenyl, cyano, C,-C4 alkylthio, nitro, 2,3-dihydrobenzafuranyl and -CO-NH-(1, 2, 3, 4-tetrahydranaphthalen-8-yl).
A heteroaryl group may be fused to a said aryl or carbocyclic group or to a further heteroaryl group or to a heterocyclic group. Examples of such fused heteroaryl groups include quinolyl, indolyl, isoindolyl, benzothiophenyl, imidazo[1,2-a]pyridyl and (3-carbolinyl groups.
As used herein, a heterocyclic group or moiety is a non-aromatic, saturated or unsaturated cyclic group or moiety containing at least one, for example, one, two or three, heteroatoms selected from N, O and S. Typically, it is a 3- to 6-membered ring. Preferably, it is a 5- or 6- membered ring containing, as heteroatoms, one or two nitrogen atoms.
Suitable heterocyclic groups and moieties include pyrazolidinyl, piperidyl, piperazinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolinyl, 3,4-dihydro-2H-pyranyl, tetrahydropyrimidinyl (for example 1,2,3,4- or 1,4,5,6-tetrahydrapyrimidinyl), 2-hydropyridinyl, 2-hydrothiazolyl, tetrahydropyridinyl (for example 1,2,5,6- or 2,3,4,5-tetrahydropyridinyl) and tetrahydropyridazinyl, for example 3,4,5,6-tetrahydropyridazinyl.

A heterocyclic group or moiety may be substituted or unsubstituted at any position., Typically, it is unsubstituted or carnes 1, 2, 3, 4 or 5 substituents. Suitable substituents include oxo, C,-C6 alkyl, C,-C6 alkylthio, C,-C6 alkoxy, C,-C6 haloalkyl, for example -CF3 and -CC13, C,-C6 haloalkoxy, for example -OCF3 and -OCCl3, halogen, hydroxy, cyano, vitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, -NR~R~~ wherein R~ and R~~ are the same or different and are hydrogen or C1-C6 alkyl, =NR, -COR, -CONR,R, -COZR, -NR,COR, -NR,COZR, -NR,CONR,R, -S(O)ZR and -S(O)zNR,R wherein each R, can be the same or different and represents hydrogen or C1-C6 alkyl and each R can be the same or different and represents C,-C6 alkyl, aryl, heteroaryl, heterocyclyl or carbocyclyl, and -S-(C,-C6 alkyl)-R~~~ and -O-(C~-C6 alkyl)-R~~~ wherein each R~~~ can be the same or different and represents aryl, heteroaryl, heterocyclyl or carbocyclyl.
Further, two substituents on the same atom can, together with the atom to which they are attached, form a carbocyclyl or heterocyclyl group.
Preferred substituents include oxo, C,-C6 alkyl, for example methyl and ethyl, C,-C6 alkoxy, for example methoxy, C1-C6 alkylthio, for example methylthio, CI-haloalkyl, for example -CF3 and -CC13, C1-C~ haloalkoxy, for example -OCF3 and -OCC13, halogen, for example chlorine and fluorine, vitro, cyano, aryl, for example phenyl, aryloxy, for example phenyloxy, arylthio, for example phenythio, heteroaryl, heteroarylthio, heterocyclyl, -CONH-(Ci-C6 alkyl), -NHCONH-R wherein R is aryl, for example phenyl, or heteroaryl, =NR~ wherein R~ is aryl, for example phenyl, or heteroaryl, -S(O)zNHR~~ wherein R~~ is aryl, for example phenyl, or heteroaryl, -S-(C1-C6 alkyl)-R~~~ wherein R~~~ is aryl, for example phenyl, or heteroaryl, and -CORD°~ wherein R~~~~ is heterocyclyl, heteroaryl or aryl.
Particularly preferred substituents are oxo, =N-aryl, for example =N-Ph, aryl, for example phenyl, halogen, C,-C4 alkyl, for example methyl and ethyl, C,-C4 alkoxy, for example methoxy and ethoxy, C1-C4 haloalkyl, for example -CF3 and -CC13 and C,-C4 haloalkoxy, for example -OCF3 and -OCC13.
Heterocyclic groups carrying one oxo substituent and up to 2, for example 0, 1 or 2, further substituents are particularly prefered.

A heterocyclic group or moiety may be fused to a further said heterocyclic group or to a said carbocyclic, aryl or heteroaryl group. Typically, it is non-fused or is fused to a benzene ring or to an iodole group. Examples of such fused heterocyclic groups include chromanyl and chromonyl groups.
An aryloxy, heteroaryloxy, heterocyclyloxy or carbocyclyloxy group is typically a said aryl, heteroaryl, heterocyclyl or carbocyclyl group attached to an oxygen atom. An arylthio, heteroarylthio, heterocyclylthio or carbocyclylthio group is typically a said aryl, heteroaryl, heterocyclyl or carbocyclyl group attached to a sulphur atom.
Typically, R~ and RZ are the same or different and represent methyl, ethyl, propyl, n-butyl or t-butyl. Preferably the groups represented by R, and Rz are unsubstituted or carry one or two substituents. Preferred substituents for R, and RZ
include C1-C4 alkyl, for example methyl and ethyl, CI-C4 alkoxy, for example methoxy and ethoxy, halogen, for example chlorine, C~-C4haloalkyl, for example -CF3 and -CC13 and C,-C4 haloalkoxy, for example -OCF3 and -OCC13. Typically, these substituents are themselves unsubstituted.
More preferably, R, and RZ are methyl or Rl and RZ together form a n-butylene group.
Z is methylene, ethylene, propylene or butylene and is preferably propylene.
Preferably Z is unsubstituted, monosubstituted or disubstituted. Preferred substituents for Z include C,-C4 alkyl, for example methyl and ethyl, Ci-C4 alkoxy, for example methoxy and ethoxy, halogen, for example chlorine, C1-C4haloalkyl, for example -CF3 and -CC13 and C,-C4 haloalkoxy, for example -OCF3 and -OCC13.
Typically, these substituents are themselves unsubstituted. Particularly preferred substituents for Z are C1-C4 alkyl groups, in particular methyl groups. A
preferred substituted alkylene group is 2,2-dimethylpropylene.
Typically, the moiety P is -Y-, -XY-, -YW- or -XYW-. Preferably, the moiety P is -XYW- or -YW-. When P is -W- or is a direct bond,. R4 is typically an aryl, heteroaryl or heterocyclyl moiety and/or is typically substituted by an aryl, heteroaryl, heterocyclyl or carbocyclyl substituent.
Typically, W is -O- or -NR3. Typically, R3 is hydrogen or is methyl, ethyl, propyl, n-butyl or t-butyl. Preferably, R3 is unsubstituted or carries one or two substituents. Preferred substituents for R3 include C,-C4 alkyl, for example methyl and ethyl, C~-C4 alkoxy, for example methoxy and ethoxy, halogen, for example chlorine, C,-C4 haloalkyl, for example -CF3 and -CCl3 and C1-C4 haloalkoxy, for example -OCF3 and -OCC13. Typically, these substituents are themselves unsubstituted.
More preferably, R3 is hydrogen or methyl, most preferably hydrogen.
V is preferably a direct bond. U is preferably -CO-, -S(O)Z-, -C(=NH)- or -C(=NOH)-, more preferably -CO-.
X is typically -NR~-. When X is a group -NR6-, R6 is typically C~-C4 alkyl, for example methyl, ethyl, propyl, n-butyl and t-butyl, aryl, for example phenyl, or heteroaryl, for example pyridyl. Preferably, R6 is unsubstituted or carries 1, 2 or 3 substituents. Preferred substituents for R6 include C~-C4 alkyl, for example methyl and ethyl, C,-C4 alkoxy such as methoxy or ethoxy, halogen, for example fluorine or chlorine, C,-C4 haloalkyl, for example -CF3 and -CC13, C,-C4 haloalkoxy, for example -OCF3 and -OCC13, cyano, vitro and -NR~R~~ wherein R~ and R~~ are the same or different and are hydrogen or C,-C4 alkyl. Typically, these substituents are themselves unsubstituted.
Preferably, X is -NH-.
Typically, the group R4 has up to 30 carbon atoms and up to 10 heteroatoms selected from N, O and S. Preferably, it has up to 25 carbon atoms and up to 7 heteroatoms. Typically, the group R4 contains at least one, preferably at least two, aryl or heteroaryl rings.
Preferably, R4 is C,-C6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, -(C,-C6 alkyl)-aryl, -(C,-C6 alkyl)-heteroaryl or -COR~~, -COzR~~ or -CONR~R~~
wherein R~ is hydrogen or C~-C6 alkyl and R~~ is an aryl, heteroaryl, carbocyclyl or heteroaryl group.
Suitable substituents for the group R4 are oxo, C1-C6 alkyl, C~-C6 alkylthio, C,-C6 alkoxy, C,-C6 haloalkyl, for example -CF3 and -CCl3, C,-C6 haloalkoxy, for example -OCF3 and -OCCl3, halogen, hydroxy, cyano, vitro, aryl, aryloxy, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, heterocyclyl, heterocyclyloxy, heterocyclythio, carbocyclyl, carbocyclyloxy, carbocyclylthio, -NR~R~~ wherein R~
and R~~ are the same or different and are hydrogen or C,-C6 alkyl, =NR, -COR, -CONR,R, -COZR, -NR,COR, -NR,COzR, -NR~CONR~R, -S(O)zR and -S(O)ZNR,R
wherein each R, can be the same or different and represents hydrogen or C1-C6 alkyl and each R can be the same or different and represents C~-C6 alkyl, aryl, heteroaryl, heterocyclyl or carbocyclyl, and -S-(C,-C6 alkyl)-R~~~ and -O-(C~-C6 alkyl)-R~~~
wherein each R~~~ can be the same or different and represents aryl, heteroaryl, heterocyclyl or carbocyclyl. Further, two substituents on the same atom can, together with the atom to which they are attached, form a carbocyclyl or heterocyclyl group.
Substituents on the group R4 may be further substituted.
Typically, when P is a direct bond, -O- or -NH-, R4 is not a moiety (A) or (B).
R.3 R.3 N (A) N
R,4 N R~4 ~ N. , R~ 1 I
R' I
wherein:
R', is: hydrogen, aryl, heteroaryl, 3- to 6- membered heterocyclyl, -(C,-C4 alkyl)-R
wherein R is aryl, heteroaryl or 3- to 6- membered heterocyclyl, C1-C4 alkyl, -CONA'z, -COA" or -SOZA" wherein each A' is the same or different and is selected from H, C,-C4 alkyl and aryl and each A" is the same or different and is selected from C~-C4 alkyl and aryl; and R'3 and R'4 are either:
(a) the same or different and selected from -COZA~wherein A~ is as defined above, -CF3, -CC13, halogen, C,-C4 alkoxy, -(C,-C4 alkyl)-aryl, -(C,-C4 alkyl)-heteroaryl, hydrogen, C,-C4 alkyl, C3-C6 carbocyclyl, 3- to 6- membered heterocyclyl, -SOZNA'z wherein A' is as defined above, and -CONZ,ZZ wherein Z, and Z2, which are the same or different, represent H, C,-C4 alkyl, aryl, heteroaryl, C3-C6 carbocyclyl, 3- to 6- membered heterocyclyl or -(C,-C4 alkyl)-R
wherein R is aryl, heteroaryl, 3- to 6- membered heterocyclyl or C3-C6 carbocyclyl, or Z, and Z2, together with the nitrogen atom to which they are attached, denote a 5- or 6- membered N-containing heterocyclic group; or (b) different, one of R'3 and R'4 being aryl or heteroaryl and the other being as defined above or R', is as defined above and R'3 and R'4 together form the divalent group, -(CH)4-, which group is optionally substituted.
Preferably, R4 is not a 3- or 5- pyrazole or a 3- indazole group when P is a direct bond, -O- or -NH-. More preferably R4 is not a pyrazole or indazole group when P is a direct bond, -O- or -NH-. More typically, R4 is not a 3- or 5-pyrazole or a 3- indazole group or, more preferably, a pyrazole or indazole group when P
does not contain the moiety U.
More preferably, when P is a direct bond, -O- or -NH- and R4 is a heteroaryl group, R4 is a pyridyl, pyrimidyl, thiazolyl or thienyl group. R4 is typically also a pyridyl, pyrimidyl, thiazolyl or thienyl group when P does not contain the moiety U
and R4 is a heteroaryl group. Suitable pyridyl, pyrimidyl, thiazolyl and thienyl groups include groups fused to a said aryl or said carbocyclic group or to a said heteroaryl or said heterocyclic group. In such compounds, R4 may be substituted by one or more of the groups mentioned above as appropriate substituents for R4.
Preferred compounds of the invention are those in which X is -NR6- wherein R6 is as defined above, and R4 is aryl or heteroaryl. In these preferred compounds, P
is typically -XYW-. Y is typically -CO-. W is typically -NR3- wherein R3 is as defined above. X is preferably -NH- and/or R4 is preferably phenyl, thienyl or pyrazolyl.
In the above preferred compounds, when R4 is phenyl it is typically substituted by a phenoxy group or by a phenylthio group, in particular a 2-phenoxy or 2-phenylthio group, or by a further phenyl group, in particular a 4-phenyl group.
When R4 is thienyl or pyrazolyl, it is typically substituted by a phenyl or phenylthio group. These substituents may be unsubstituted or may be further substituted at any position. Typically, they are unsubstituted or carry one, two or three further substituents. Preferred further substituents include halogen, for example chlorine and fluorine, C,-C4 alkyl, for example methyl and ethyl, C~-C4 alkoxy, for example methoxy and ethoxy, C,-C4 haloalkyl, for example -CF3 and -CCl3, and -S(O)ZNH-phenyl. These further substituents are typically themselves unsubstituted.
In the above preferred compounds of the invention, R4 is preferably 2-phenoxyphenyl, 2-fluoro-diphen-4-yl, 5-(4-chlorophenylthio)-thien-3-yl, 4-(4-fluorophenyl)-thien-2-yl, 5-(4-chlorophenyl)-1-(3,4-dichlorophenyl)-pyrazol-3-yl Or -(C6Ha)-S-(C6Ha)-S(O)z-~-(C6H4O
Further preferred compounds of the invention are those in which P is -YW-and R4 is an aryl, heterocyclyl or heteroaryl group. In these further preferred compounds, Y is typically -CO-. W is typically -NR3- wherein R3 is as defined above. Further, R4 is preferably an oxo-substituted heterocyclic group such as a chromonyl group or is a pyrazolyl, thienyl, phenyl or indolyl group.
In the above further preferred compounds, R4 is typically unsubstituted or substituted by one or more, for example, one, two or three substituents selected from C,-C6 alkyl, for example t-butyl, phenyl, thiazolyl, phenylthio, cyano, nitro, alkylthio, for example i-propylthio, C1-C6 alkoxy, halogen such as chlorine and -S-(C,-C4 alkyl)-phenyl. These substituents may be unsubstituted or may be substituted at any position. Typically, they are unsubstituted or carry one, two or three further substituents. Preferred further substituents include halogen, for example chlorine, C,-C4 haloalkyl, for example -CF3, phenyl and -S(O)2-NH-phenyl.
These further substituents are typically themselves unsubstituted.
Additional preferred compounds of the invention are those in which P is -W-or -YW- wherein Y is -CO- and W is -O-.
Particularly preferred compounds of the invention are compounds of formula (h) and pharmaceutically acceptable salts thereof, (~

wherein:
- R, and RZ are the same or different and each represent a C,-C6 alkyl group, or Rl and RZ together form an allcylene group having from 3 to . 6 carbon atoms;
- Z is an alkylene group having from 2 to 4 carbon atoms;
- R3 is hydrogen or C,-C6 alkyl;
- Y is -CO- or -S(O)2-;
- X is a direct bond or -NR6- wherein R6 is hydrogen, C,-C6 alkyl, CZ-C6 alkenyl, CZ-C6 alkynyl, aryl or heteroaryl; and - R4 is C,-C6 alkyl, CZ-C6 alkenyl, CZ-C6 alkynyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, a group -R-A wherein R is -(C,-C6 alkyl)-, -(Cz-C6 alkenyl)- or -(CZ-C6 alkynyl)- and A is aryl, heteroaryl, carbocycyl or heterocyclyl, or R4 is a group -CORD or -COZR~ wherein 1 S R~ is aryl, heteroaryl, carbocyclyl or heterocyclyl.
Further particularly preferred compounds of the invention are compounds of formula (I~~), and pharmaceutically acceptable salts thereof O
RawX N~NR R (h/) ( i 2 wherein R1 and RZ are methyl or together form a n-butylene group, R3 is hydrogen or methyl, R4 is as defined in the formula (I) or in the formula (h) and X is a direct bond or is -NR6- wherein R6 is as defined above. Preferably, when X
in the formula (h~) is -NR6-, R4 is as defined as in the above preferred compounds of the invention. Preferably, when X in the formula (I~~) is a direct bond, R4 is as defined in the above further preferred compounds of the invention.
The present invention includes pharmaceutically acceptable salts of the compounds of the invention. Suitable salts include salts with pharmaceutically acceptable acids, both inorganic acids such as hydrochloric, sulphuric, phosphoric, diphosphoric, hydrobromic or nitric acid and organic acids such as citric, fumaric, malefic, malic, ascorbic, succininc, tartaric, benzoic, acetic, methanesulphonic, ethanesulphonic, benzenesulphonic or p-toluenesulphonic acid. Salts may also be formed with pharmaceutically acceptable bases such as alkali metal (eg sodium or potassium) and alkali earth metal (eg calcium or magnesium) hydroxides and organic bases such as alkyl amines, aralkyl amines or heterocyclic amines.
Particularly preferred compounds of the invention are:
1-(3-Dimethylamino-propyl)-3-(2-phenoxy-phenyl)-urea 1-[2-(4-Chloro-phenoxy)-pyridin-3-yl]-3-(3-dimethylaminopropyl)-urea 1-(3-Dimethylamino-propyl)-3-pyren-1-ylmethyl-urea 1-(3-Dimethylamino-propyl)-3-[( 1 R,2R)-5-phenyl-2-( 1-phenyl-methanoyl)-cyclohexyl]-urea 1-(3-Dimethylamino-propyl)-3-[2-(4-phenoxy-phenyl)-ethyl]-urea 1-(3-Dimethylamino-propyl)-3-[3-methyl-5-(4-methyl-[1,2,3]thiadiazol-5-yl)-1-(4-trifluoromethoxy-phenyl)-1 H-pyrazol-4-yl]-urea 2'-[3-(3-Dimethylamino-propyl)-ureido]-biphenyl-2-carboxylic acid (4-fluoro-phenyl)-amide N-(3-Chloro-4-methyl-phenyl)-4-[3-(3-dimethylamino-propyl)-ureido]-3-phenyl-butyramide 1-[4-(4-Chloro-phenylsulfanyl)-thiophen-3-yl]-3-(3-dimethylamino-propyl)-urea 1-[2-(3,4-Dimethoxy-phenyl)-6-methyl-quinolin-4-yl]-3-(4-dimethylamino-propyl)-urea 1-(6-Bromo-2-thiophen-3-yl-quinolin-4-yl)-3-(3-dimethylamino-propyl)-urea 1-[3-(4-Chloro-phenyl)-4-cyano-5-isobutylsulfanyl-thiophen-2-yl]-3-(3-dimethylamino-propyl)-urea 1-[6-(2,4-Dichloro-phenyl)-cyclohex-3-enyl]-3-(3-dimethylamino-propyl)-urea 1-(2-Benzylsulfanyl-phenyl)-3-(3-dimethylamino-propyl)-urea Z- {2-[3-(3-Dimethylamino-propyl)-ureido]-phenylsulfanyl} -N-phenyl-benzenesulfonamide 1-(3-Dimethylamino-propyl)-3-(2'-fluoro-biphenyl-4-yl)-urea N-(3,5-Dichloro-phenyl)-2- {3-[3-(3-dimethylamino-propyl)-ureido]-pyridin-2-ylsulfanyl}-acetamide 1-(3-Dimethylamino-propyl)-3- {2-[ 1-(1-trifluoromethyl-1,3,4,9-tetrahydro-b-carbolin-2-yl)-methanoyl]-phenyl}-urea 8-{2-[3-(3-Dimethylamino-propyl)-ureido]-phenylsulfanyl}-naphthalene-1-carboxylic acid methylamide 1-[ 1-(3,4-Dichloro-benzyl)-6-oxo-1,6-dihydro-pyridin-3-yl]-3-(3-dimethylamino-propyl)-urea 1-(3-Dimethylamino-propyl)-3-(3-oxo-I ,2,3-triphenyl-propyl)-urea 1-[5-(4-Chloro-phenyl)-1-(3,4-dichloro-phenyl)-1H pyrazol-3-yl]-3-(3-dimethylamino-propyl)-urea 1- {4-[4-(4-Chloro-phenyl)-thiazol-2-yl]-phenyl} -3-(3-dimethylamino-. propyl)-urea 1-(3-Dimethylamino-propyl)-3-[5-(4-fluoro-phenyl)-thiophen-2-yl]-urea 1-[3-(4-tert-Butyl-benzyloxy)-thiophen-2-yl]-3-(3-dimethylamino-propyl)-urea 1-(3-Dimethylamino-propyl)-3-[4-(4-phenyl-thiazol-2-yl)-phenyl]-urea 1-[3-(3,4-Dichloro-benzylsulfanyl)-thiophen-2-yl]-3-(3-dimethylamino-propyl)-urea 1-[2-(5-Chloro-1-methyl-3-phenyl-1H pyrazol-4-ylmethylsulfanyl)-phenyl]-3-(3-dimethylamino-propyl)-urea 1-[2-(4-Chloro-benzylsulfanyl)-3-methyl-4-oxo-3,4-dihydro-quinazolin-7-yl]-3-(3-dimethylamino-propyl)-urea 1-(3-Dimethylamino-propyl)-3- {4-[4-(4-methoxy-phenyl)-pyrimidin-2-ylsulfanylmethyl]-phenyl} -urea 1-(4-Bromophenyl)-3-(3-(1-pyrrolidinyl) propyl) urea 1-(4-Bromophenyl)-3-(3-dimethylamino propyl) urea 3-(4-Bromophenyl)-1-methyl-1-(3-dimethylamino propyl) urea 1-(3-Phenyl-5-methoxy phenyl)-3-(3-dimethylamino propyl) urea 3-(4-Chlorophenyl)-1-methyl-1-(3-dimethylamino propyl) urea 1-(3-Nitrophenyl)-1-benzyl-3-(3-dimethylamino propyl) urea 1-Benzyl-1-(4-methyl-3-pyridinyl)-3-(3-dimethylamino propyl) urea 1-Methyl-1-(3,5-bistrifluoromethylphenyl)-3-(3-dimethylaminopropyl)urea 1-(2-Phenacyl-4-chorophenyl)-1-methyl-3-(3-dimethylamino propyl) urea 1-(2-Chloro-4-trifluoromethylphenyl)-3-(3-dimethylaminopropyl) urea 1-(3-Fluoro-5-trifluoromethylphenyl)-3-(3-dimethylaminopropyl) urea 1-(3-N-tent-butoxycarbonyl-benzylamino)-3-(3-dimethylaminopropyl) urea N-(3-Dimethylamino-propyl)-2-[ 1-(4-fluorobenzoyl]-benzamide 2-[ 1-(4-Chlorobenzoyl]-N-(3-dimethylamino-propyl)-benzamide 5-(4-Chloro-phenyl)-1-phenyl-1H pyrazole-3-carboxylic acid (3-dimethylamino-propyl)-amide 5-Chloro-3-phenyl-1H indole-2-carboxylic acid (3-dimethylamino-propyl)-amide N-(3-Dimethylamino-propyl)-2-(2-phenylsulfamoyl-phenylsulfanyl)-benzamide 2-Benzylsulfanyl-N-(3-dimethylamino-propyl)-benzamide 6,8-Di-tert-butyl-4-oxo-4H chromene-2-carboxylic acid (3-dimethylamino -propyl)-amide 3-(4-Chloro-phenyl)-4-cyano-5-isobutylsulfanyl-thiophene-2-carboxylic acid (3-dimethylamino-propyl)-amide 4-(4-Chloro-phenoxy)-N-(3-dimethylamino-propyl)-3-nitro-benzamide N-(3-Dimethylamino-propyl)-4-(4-phenyl-thiazol-2-yl)-benzamide 1-(3-Dimethylamino-propyl)-3-(2-phenoxyphenyl)-urea 1-[4-(4-Chloro-phenylsulfanyl)-thiophen-3-yl]-3-(3-dimethylamino-propyl) -urea 1-(3-Dimethylamino-propyl)-3-(2'-fluoro-biphenyl-4-yl)-urea N-(3-Dimethylamino-propyl)-2-[ 1-(4-fluorobenzoyl]-benzamide N-(3-Dimethylamino-propyl)-3-phenoxy-benzamide N-(3-Dimethylamino-propyl)-2-phenoxy-benzamide 2-(4-Chloro-phenoxy)-N-(3-dimethylamino-propyl)-nicotinamide 4'-n-Propyl-biphenyl-4-carboxylic acid (3-dimethylamino-propyl)-amide 2-[1-(4-Bromo-phenyl)-methanoyl]-cyclohexanecarboxylic acid (3-dimethylamino-propyl)-ami de 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid (3-dimethylamino-propyl)-amide 2-[ 1-(4-Chlorobenzoyl]-N-(3-dimethylamino-propyl)-benzamide 2-Phenyl-quinoline-4-carboxylic acid (3-dimethylamino-propyl)-amide 2-[ 1-(4-Chloro-3-nitrobenzoyl)]-N-(3-dimethylamino-propyl)-benzamide N-(3-Dimethylamino-propyl)-2-pyren-1-yl-acetamide N-(3-Dimethylamino-propyl)-2-[1-(3-methyl-benzo[b]thiophen-2-yl)-methanoyl]-benzamide 4-Chloro-N-(3-dimethylamino-propyl)-2-phenoxy-benzamide N-(3-Dimethylamino-propyl)-3-(4-phenoxy-phenyl)-propionamide N-(3-Dimethylamino-propyl)-2-[ 1-( 1-trifluoromethyl-1,3,4,9-tetrahydro-b-carbolin-2-yl)-methanoyl]-benzamide 1-(4-Chloro-phenyl)-2,5-dimethyl-1-pyrrole-3-carboxylic acid (3-dimethylamino-propyl)-amide 2- { 1-[(3-Dimethylamino-propylcarbamoyl)-methyl]-cyclopentyl} -N-(4-trifluoromethoxy-phenyl)-acetamide 8-[2-(3-Dimethylamino-propylcarbamoyl)-phenylsulfanyl]-naphthalene-1-carboxylic acid methylamide 3-Methyl-5-(4-methyl-[1,2,3]thiadiazol-5-yl)-1-(4-trifluoromethoxy-phenyl)-1H pyrazole-4-carboxylic acid (3-dimethylamino-propyl)-amide 6,8-Di-tert-butyl-4-oxo-4H-chromene-2-carboxylic acid (3-dimethylamino-propyl)-amide 2-(Furan-2-yl)-quinoline-4-carboxylic acid (3-dimethylamino-propyl)-amide Biphenyl-2,2'-dicarboxylic acid 2'-[(3-dimethylamino-propyl)-amide]-2-[(4-fluoro-phenyl)-amide]
3-Phenyl-pentanedioic acid (3-chloro-4-methyl-phenyl)-amide (3-dimethylamino-propyl)-amide 2-(3,4-Dimethoxy-phenyl)-6-methyl-quinoline-4-carboxylic acid (3-dimethylamino-propyl)-ami de 6-Bromo-(2-thiophen-3-yl)-quinoline-4-carboxylic acid (3-dimethylamino-propyl)-amide 3-(4-Chloro-phenyl)-4-cyano-S-isobutylsulfanyl-thiophene-2-carboxylic acid (3-dimethylamino-propyl)-amide 4-(4-Chloro-phenoxy)-N-(3-dimethylamino-propyl)-3-nitro-benzamide 6-(2,4-Dichloro-phenyl)-cyclohex-3-ene carboxylic acid (3-dimethylamino-propyl)-amide N-(3-Dimethylamino-propyl)-2-(2-phenylsulfamoyl-phenylsulfanyl)-benzamide 2'-Fluoro-[1,1'-biphenyl]-4-carboxylic acid (3-dimethylamino-propyl)-amide 2-Benzylsulfanyl-N-(3-dimethylamino-propyl)-benzamide Pyrazine-2,3-dicarboxylic acid 2-[(3-dimethylamino-propyl)-amide] 3-[(5 , 6, 7, 8-tetrahydro-naphthal en-1-yl)-amide]
2-[(3,5-Dichloro-phenylcarbamoyl)-methylsulfanyl]-N-(3-dimethylamino-propyl)-nicotinamide 2-(3-Trifluoromethyl-phenyl)-thiazole-4-carboxylic acid (3-dimethylamino-propyl)-amide 2-(4-Chloro-phenyl)-thiazole-4-carboxylic acid (3-dimethylamino-propyl)-amide 5-Chloro-1-(2,4-dichloro-benzyl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid (3-dimethylamino-propyl)-amide 1-(2,4-Dichloro-benzyl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid (3-dimethylamino-propyl)-amide 5-Chloro-1-(3,4-dichloro-benzyl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid (3-dimethylamino-propyl)-amide 1-(3,4-Dichloro-benzyl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid (3-dimethylamino-propyl)-amide 5-Chloro-1-(2,6-dichloro-benzyl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid (3-dimethylamino-propyl)-amide 1,1-Dimethyl-indan-4-carboxylic acid (3-dimethylamino-propyl)-amide N-(3-Dimethylamino-propyl)-2-[ 1-(4-ethyl-phenyl)-methanoyl]-benzamide N-(3-Dimethylamino-propyl)-3-(2,4,5-trimethyl-phenyl)-butyramide 2-[3-(3,4-Dichloro-phenyl)-ureido]-N-(3-dimethylamino-propyl)-benzamide N-(3-Dimethylamino-propyl)-4-oxo-2,3,4-triphenyl-butyramide 5-(4-Chloro-phenylsulfanyl)-[1,2,3]thiadiazole-4-carboxylic acid (3-dimethylamino-propyl)-amide 2-(3-Chloro-5-trifluoromethyl-pyridin-2-ylsulfanyl)-3-methyl-3H imidazole-4-carboxylic acid (3-dimethylamino-propyl)-amide 2-(2-Chloro-4-trifluoromethyl-phenyl)-[1,3]-thiazole-4-carboxylic acid (3-dimethylamino-propyl)-amide 2-(2,3-Dihydro-1-benzofuran-5-yl)-1,3-thiazole-4-carboxylic acid (3-dimethylamino-propyl)-amide 2-(2,3-Dichloro-phenyl)-1,3-thiazole-4-carboxylic acid (3-dimethylamino-propyl)-amide 4-[4-(4-Chloro-phenyl)-thiazol-2-yl]-N-(3-dimethylamino-propyl)-benzamide 5-(4-Fluoro-phenyl)-thiophene-2-carboxylic acid (3-dimethylamino-propyl)-amide 4-Methyl-2-(3-trifluoromethyl-phenyl)-thiazole-5-carboxylic acid (3-dimethylamino-propyl)-amide . 3-(4-tert-Butyl-benzyloxy)-thiophene-2-carboxylic acid (3-dimethylamino-propyl)-amide 4-Oxo-3-(3-trifluoromethyl-phenyl)-3,4-dihydro-phthalazine-1-carboxylic acid (3-dimethylamino-propyl)-amide 2-(4-Chloro-phenyl)-N-(3-dimethylamino-propyl)-4-oxo-4-phenyl-butyramide 5-(4-Chloro-phenyl)-1-phenyl-1H pyrazole-3-carboxylic acid (3-dimethylamino-propyl)-amide N-(3-Dimethylamino-propyl)-4-(4-phenyl-thiazol-2-yl)-benzamide 1-(2,4,5-Trichloro-phenylsulfonyl)-pyrrolidine-2-carboxylic acid (3-dimethylamino-propyl)-amide 3-(3,4-Dichloro-benzylsulfanyl)-thiophene-2-carboxylic acid (3-dimethylamino-propyl)-amide 5-Chloro-3-phenyl-1H indole-2-carboxylic acid (3-dimethylamino-propyl)-amide N-(3-Dimethylamino-propyl)-2-[1-(4-fluoro-benzyl)-1H indol-3-yl]-acetamide 2-Phenyl-imidazo[1,2-a]pyridine-3-carboxylic acid (3-dimethylamino-propyl)-amide N-(3-Dimethylamino-propyl)-2-(7-ethyl-1H indol-3-yl)-4-oxo-4-phenyl-butyramide Phenyl-trifluoromethyl-thieno[3,2-b]pyridine-2-carboxylic acid (3-dimethylamino-propyl)-amide 3-(4-Nitro-3-trifluoromethyl-phenoxy)-thiophene-2-carboxylic acid (3-dimethylamino-propyl)-amide 2-(5-Chloro-1-methyl-3-phenyl-1H-pyrazol-4-ylmethylsulfanyl)-N-(3-1 S dimethylamino-propyl)-benzamide 2-(4-Chloro-benzylsulfanyl)-3-methyl-4-oxo-3,4-dihydro-quinazoline-7 -carboxylic acid (3-dimethylamino-propyl)-amide N-(3-Dimethylamino-propyl)-4-[4-(4-methoxy-phenyl)-pyrimidin-2 -ylsulfanylmethyl]-benzamide 1-(4-chlorobenzyl)-3-(2-N,N-dimethylethylamido)-6-pyridone 1-(2,6-dichlorobenzyl)-3-(3-N,N-dimethylpropylamido)-6-pyridone 1-(3-trifluoromethylbenzyl)-3-(2-N,N-dimethylethylamido)-2-pyridone 1-(2,6-dichlorobenzyl)-3-(2-N,N-dimethylethylamido)-2-pyridone 1-(3,4-dichlorobenzyl)-3-(N-[2,N,N-dimethylaminoethylamido])-2-pyridone 1-(2,6-dichlorobenzyl)-3-(N-[2-N,N-dimethylaminoethylamido])-6-pyridone 5-chloro-1-(3,4-dichlorobenzyl)-3-(2-N,N-dimethylaminoethylamido)-6 -pyridone S-chloro-3-(2-N,N-dimethylaminoethylamido)-1-(3-trifluoromethylbenzyl)-6-pyridone 5-chloro-1-(3,4-dichlorobenzyl)-3-N-(2-[N',N'-dimethylaminoethylamido])-2-pyridone 5-chloro-1-(4-chlorobenzyl)-3-N-(2-(N',N'-dimethylamino)ethyl)amido-2-pyridone 5-chloro-1-(3-trifluoromethylbenzyl)-3-N-(2-(N',N'-dimethylamino)ethyl) amido-2-pyridone 1-benzyl-5-chloro-3-N-(2-[N',N'-dimethylamino]ethyl)carboXamido-6-pyridone 5-chloro-1-(4-chlorobenzyl)-3-N-(2-[N',N'-dimethylamino]ethyl)carboxamido -6-pyridone 4-(2,4-dichlorobenzoyl)pyrrole-2-N-dimethylaminopropylcarboxamide 4-[(N-[3-(N',N'-dimethylaminopropyl)]carboxamido]-2-phenylthiazo1e 4-(N-(3-N',N'-dimethylaminopropyl)carboxamido)-2-(4-pyridinyl)thiazole 2-[4-(N-[3-N',N'-dimethylaminopropyl]carboxamido)phenyl-4-(3-trifluoromethylphenyl)]thiazole 4-(4-chlorophenyl)-2-(4-[3-N',N'-dimethylaminopropyl]carboxamido)phenyl) 15. thiazole 1-(3,5-bis(trifluoromethyl)benzyl)-3-[N-(2-dimethylaminoethyl) carboxamido]-2 [ 1 H]-pyridone N-(3-dimethylaminopropyl)-4-(3-chloro-5-trifluoromethyl-2-pyridyloxy) phenylsulfonamide N 1-[3-(dimethylamino)propyl]-3-[3-chloro-5 -(trifluoromethyl)-2-pyridyl]
propanamide 3-(N-(2-dimethylaminoethyl)carboxamido]-1-(4-trifluoromethylbenzy1))-2 [1H]-pyridone 1-ethyl-3-(3-dimethylaminopropyl)urea 1-(3-(dimethylamino)-propyl)-3-phenylurea N1-[2-(2,4-dichlorophenoxy)phenyl]-N2-[3-(dimethylamino)propyl]
ethanediamide N4-[3-(dimethylamino)propyl]-3-(2,6-dichlorophenyl)-5-methylisoxazole-4-c arboxamide N-[[3-(2,6-dichlorophenyl)-5-methylisoxazol-4-yl]carbonyl]-N'-[3-(dimethyla mino)propyl]urea N-(4-chlorophenyl)-N'-[3-dimethylaminopropyl]urea N-(3,5-Dichloro-phenyl)-3-(3-dimethylamino-propylamino)-propionamide [3-(2-Ethyl-6-methyl-pyridin-3-yloxy)-propyl]-dimethyl-amine 8-(3-Dimethylamino-propoxy)-1,3,7-trimethyl-3,7-dihydro-purine-2,6-dione 2-(3-Dimethylamino-propylamino)-isophthalonitrile Dimethylamino-(3-methyl-benzo[b]thiophen-2-yl)-propan-1-one (HCl) N-Benzo[ 1,3]dioxol-5-ylmethyl-N,N-dimethyl-propane-1,3-diamine N,N-Dimethyl-N-(5-vitro-quinolin-8-yl)-propane-1,3-diamine 1-(4-Chloro-phenyl)-3-(3-dimethylamino-propyl)-urea 2-Amino-N-(3-dimethylamino-propyl)-b enzamide 3-Phenyl-acrylic acid 3-dimethylamino-propyl ester 3,5-Dinitro-benzoic acid 2-dimethylamino-ethyl ester [4-(4-Bromo-phenyl)-3-(3-dimethylamino-propyl)-3H-thiazol-2-ylidene]-phenyl-amine 3-Methyl-benzofuran-2-carboxylic acid dimethylamino-dimethyl-propyl ester N'-(2-Chloro-4-vitro-phenyl)-N,N-dimethyl-propane-1,3-diamine [3-(3-Dimethylamino-propyl)-5-(4-vitro-phenyl)-3H-thiazol-2-ylidene]-phenyl-amine [3-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-dimethyl-amine 2,3-Dimethyl-1H-indole-5-carboxylic acid 2-dimethylamino-ethyl ester N'-(3,4-Dinitro-5-pyridin-2-yl-thiophen-2-yl)-N,N-dimethyl-propane-1,3-diamine Cyclooctyl-dithiocarbamic acid 2-dimethylamino-ethyl ester (HCl) N-(2,6-Difluoro-phenyl)-C-dimethylamino-acetamide 2-Acetylamino-3-(4-chloro-phenyl)-N-(3-dimethylamino-propyl)-acrylamide N-[2-[5-(4-Bromo-phenyl)-furan-2-yl]-1-(3-dimethylamino-propyl carbamoyl)-vinyl]-4-methyl-benzamide 2,6-Bis-(3-dimethylamino-propylamino)-3-vitro-benzonitrile 3 0 N-[2-(2,4-Dichloro-phenoxy)-phenyl]-N'-(3-dimethylamino-propyl)-oxalamide 3,5-Dichloro-N-(3-dimethylamino-propyl)-2,6-dimethoxy-benzamide 2-Dimethylaminomethyl-3,4-dihydro-2H-naphthalen-1-one (HCl) 2-( { 1-[N-(3-Dimethylamino-propyl)-3-trifluoromethyl-phenyl]-methanimidoyl}-amino)-6-fluoro-benzoic acid S 2,4-Dichloro-N-(3-dimethylamino-propyl)-N'-hydroxy-benzamidine 3-(3-Methyl-ureido)-4-oxo-3,4-dihydro-quinazoline-2-carboxylic acid (3-dimethylamino-propyl)-amide 5-Bromo-N-(3-dimethylamino-propyl)-2-hydroxy-benzamide N-(2,4-Dichloro-phenyl)-6-(2-dimethylamino-ethylsulfanyl)-4-trifluoromethyl-nicotinamide 1-(2,6-Dichloro-benzyl)-2-oxo-1,2-dihydro-pyridine-3-carboxylic acid (2-dimethylamino-ethyl)-amide 3-Amino-4-oxo-3,4-dihydro-quinazoline-2-carboxylic acid (3-dimethylamino-propyl)-amide Certain compounds of the invention are novel. Thus, the present invention also provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, in which Rl, RZ, Z, R3, Y, X and R4 are as defined above except for:
2-Benzylsulfanyl-N-(3-dimethylamino-propyl)-benzamide N-(3-Dimethylamino-propyl)-3-phenoxy-benzamide 1-(4-chlorobenzyl)-3-(2-N,N-dimethylethylamido)-6-pyridone 1-(2,6-dichlorobenzyl)-3-(3-N,N-dimethylpropylamido)-6-pyridone 1-(3-trifluoromethylbenzyl)-3-(2-N,N-dimethylethylamido)-2-pyridone 1-(2,6-dichlorobenzyl)-3-(2-N,N-dimethylethylamido)-2-pyridone 1-(3,4-dichlorobenzyl)-3-(N-[2,N,N-dimethylaminoethylamido])-2-pyridone 1-(2,6-dichlorobenzyl)-3-(N-[2-N,N-dimethylaminoethylamido])-6-pyridone 5-chloro-1-(3,4-dichlorobenzyl)-3-(2-N,N-dimethylaminoethylamido)-6-pyridone 5-chloro-3-(2-N,N-dimethylaminoethylamido)-1-(3-trifluoromethylbenzyl)-6-pyridone 5-chloro-1-(3,4-dichlorobenzyl)-3-N-(2-[N',N'-dimethylaminoethylamido])-2-pyridone S-chloro-1-(4-chlorobenzyl)-3-N-(2-(N',N'-dimethylamino)ethyl)amido-2-pyridone 5-chloro-1-(3-trifluoromethylbenzyl)-3-N-(2-(N',N'-dimethylamino)ethyl) amido-2-pyridone 1-benzyl-5-chloro-3-N-(2-[N',N'-dimethylamino]ethyl)carboxamido-6-pyridone 5-chloro-1-(4-chlorobenzyl)-3-N-(2-[N',N'-dimethylamino] ethyl) carboxamido-6-pyridone 4-(2,4-dichlorobenzoyl)pyrrole-2-N-dimethylaminopropylcarboxamide 4-[(N-[3-(N',N'-dimethylaminopropyl)]carboxamido]-2-phenylthiazo1e 4-(N-(3-N',N'-dimethylaminopropyl)carboxamido)-2-(4-pyridinyl)thiazole 2-[4-(N-[3-N',N'-dimethylaminopropyl]carboxamido)phenyl-4-(3-trifluoromethylphenyl]thiazole 4-(4-chlorophenyl)-2-(4-[3-N',N'-dimethylaminopropyl]carboxamido)phenyl) thiazole 1-(3,5-bis(trofluoromethyl)benzyl)-3-[N-(2-dimethylaminoethyl) carboxamido]-2 [ 1 H]-pyridone N-(3-dimethylaminopropyl)-4-(3-chloro-5-trifluoromethyl-2-pyridyloxy) phenylsulfonamide N1-[3-(dimethylamino)propyl]-3-[3-chloro-5-(trifluoromethyl)-2-pyridyl]
propanamide 3-(N-(2-dimethylaminoethyl)carboxamido]-1-(4-trifluoromethylbenzy1))-2 [ 1 H]-pyridone 1-ethyl-3-(3-dimethylaminopropyl)urea 1-(3-(dimethylamino)-propyl)-3-phenylurea N1-[2-(2,4-dichlorophenoxy)phenyl]-N2-[3-(dimethylamino)propyl]
ethanediamide N4-[3-(dimethylamino)propyl]-3-(2,6-dichlorophenyl)-5-methylisoxazole-4-c arboxamide N-[[3-(2,6-dichlorophenyl)-S-methylisoxazol-4-yl]carbonyl]-N'-[3-(dimethylamino)propyl]urea SUBSTITUTE SHEET (RULE 26) N-(4-chlorophenyl)-N'-[3-dimethylaminopropyl]urea N-(3,5-Dichloro-phenyl)-3-(3-dimethylamino-propylamino)-propionamide [3-(2-Ethyl-6-methyl-pyridin-3-yloxy)-propyl]-dimethyl-amine 8-(3-Dimethylamino-propoxy)-1,3,7-trimethyl-3,7-dihydro-purine-2,6-dione 2-(3-Dimethylamino-propylamino)-isophthalonitrile Dimethylamino-(3-methyl-benzo[b]thiophen-2-yl)-propan-1-one (HCl) N-B enzo [ 1, 3 ] dioxol-5 -ylmethyl-N,N-dimethyl-prop ane-1, 3 -di amin a N,N-Dimethyl-N-(5-vitro-quinolin-8-yl)-propane-1,3-diamine 1-(4-Chloro-phenyl)-3-(3-dimethylamino-propyl)-urea 2-Amino-N-(3-dimethylamino-propyl)-benzamide 3-Phenyl-acrylic acid 3-dimethylamino-propyl ester 3,5-Dinitro-benzoic acid 2-dimethylamino-ethyl ester [4-(4-Bromo-phenyl)-3-(3-dimethylamino-propyl)-3H-thiazol-2-ylidene]-phenyl-amine 3-Methyl-benzofuran-2-carboxylic acid dimethylamino-dimethyl-propyl ester N'-(2-Chloro-4-vitro-phenyl)-N,N-dimethyl-propane-1,3-diamine [3-(3-Dimethylamino-propyl)-5-(4-vitro-phenyl)-3H-thiazol-2-ylidene]-phenyl-amine [3-( 10,11-Dihydro-dibenzo [a,d]cyclohepten-5-ylidene)-propyl]-dimethyl-amine 2,3-Dimethyl-1H-indole-5-carboxylic acid 2-dimethylamino-ethyl ester N'-(3,4-Dinitro-5-pyridin-2-yl-thiophen-2-yl)-N,N-dimethyl-propane-1,3-diamine Cyclooctyl-dithiocarbamic acid 2-dimethylamino-ethyl ester (HCl) N-(2,6-Difluoro-phenyl)-C-dimethylamino-acetamide 2-Acetylamino-3-(4-chloro-phenyl)-N-(3-dimethylamino-propyl)-acrylamide N-[2-[5-(4-Bromo-phenyl)-furan-2-yl]-1-(3-dimethylamino-propylcarbamoyl)-vinyl]-4-methyl-benzamide 2,6-Bis-(3-dimethylamino-propylamino)-3-vitro-benzonitrile N-[2-(2,4-Dichloro-phenoxy)-phenyl]-N'-(3-dimethylamino-propyl)-oxalamide SUBSTITUTE SHEET (RULE 26) 3,5-Dichloro-N-(3-dimethylamino-propyl)-2,6-dimethoxy-benzamide 2-Dimethylaminomethyl-3,4-dihydro-2H-naphthalen-1-one (HCl) 2-( { 1-[N-(3-Dimethylamino-propyl)-3-trifluoromethyl-phenyl]-methanimidoyl)-amino)-6-fluoro-benzoic acid 2,4-Dichloro-N-(3-dimethylamino-propyl)-N'-hydroxy-benzamidine 3-(3-Methyl-ureido)-4-oxo-3,4-dihydro-quinazoline-2-carboxylic acid (3-dimethylamino-propyl)-amide 5-Bromo-N-(3-dimethylamino-propyl)-2-hydroxy-benzamide N-(2,4-Dichloro-phenyl)-6-(2-dimethylamino-ethylsulfanyl)-4 trifluoromethyl-nicotinamide 1-(2,6-Dichloro-benzyl)-2-oxo-1,2-dihydro-pyridine-3-carboxylic acid (2-dimethylamino-ethyl)-amide 3-Amino-4-oxo-3,4-dihydro-quinazoline-2-carboxylic acid (3-dimethylamino-propyl)-amide Compounds of the invention in which P is -U-W- may be prepared by reacting a compound of formula (II) Z
/ \

wherein Z, R~ and RZ are as defined above and W~ is a group WH wherein W
is as defined above, with a compound of formula (III) R.a-~ ( wherein R4 is as defined above and U~ is a group -UL wherein U is as defined above and L is a hydroxy group or a leaving group such as a halogen atom.

Compounds of formulae (II) and (III) are known compounds, or may be prepared by analogy with known methods.
Typically, the reaction takes place in the presence of a base such as diisopropylethylamine or the equivalent polymer bound resin N,N
(diisopropyl)amino-methylpolystyrene resin (PS-DIEA), and a coupling agent such as O-(7-azabenzotriazol-1-yl)-N,N,N,N tetramethyluronium hexafluorophosphate (HATI~. The reaction typically takes place in a solvent such as acetonitrile at a temperature of from 0 to 100 °C, preferably from 20 to 80 °C.
The work-up typically involves the use of a sequestration enabling reagent such as tetrafluorophthalic anhydride and polymer bound scavenger resins to remove unwanted starting materials. Such techniques are described in Parlow et al Tetrahedron Lett., 1997, 38, 7959.
Compounds of the invention wherein P is -NH-CO-W- can be prepared by reacting a compound of formula (II) above with a compound of formula (IV) R4-N=C=O (IV) wherein R4 is as defined above.
Typically, the reaction takes place in a hydrocarbon solvent such as toluene at a temperature of from 0 to 100 °C. The work-up typically involves the use of a sequestration enabling reagent such as tetrafluorophthalic anhydride and polymer bound scavenger resins to remove unwanted starting materials. The amides thereby prepared may be converted to the corresponding amidines by standard methods.
The compounds of formula (IV) may be prepared by techniques known in the art. For example, they may be prepared by reacting a compound of formula (V) O
( wherein R4 is as defined above, with diphenylphosphoryl azide (DPPA), in the presence of a base such as triethylamine. Typically, the reaction takes place under reflux, in a solvent such as toluene. Compounds of formula (V) are known compounds or may be prepared by analogy with known methods.
Compounds of the invention wherein P is -X-U-W- wherein X, U and W are as defined above can be prepared by reacting a compound of formula (II) above with a compound of formula (VI) ~~ ~U~
X L
wherein R4, X and U are as defined above and L is a hydroxy group or leaving group such as a 4-nitro-phenoxy group. Typically, the reaction takes place in a hydrocarbon solvent such as tetrahydrofuran at a temperature of from 60 to 70 °C.
The work-up typically involves the use of a sequestration enabling reagent such as tetrafluorophthalic anhydride and polymer bound scavenger resins to remove unwanted starting material.
The compounds of formula (VI) are known compounds or may be prepared by analogy with known methods. For example, compounds of formula (VI) in which U is -CO- can be prepared by reacting a compound of formula (VII) ( wherein R4 and X are as defined above, with a chloroformate, for example an aromatic chloroformate such as 4-nitrophenyl chloroformate. Typically, the reaction takes place under reflux, in a solvent such as anhydrous THF. Further, compounds of formula (VI) in which U is -C-(=NH)- can, for example, be prepared from the corresponding nitrite of formula R4-X-C=N, for example by reaction with hydrochloric acid.
Compounds of the invention in which P is -X-Y- or -X-Y-W- and R4 is other than -COR~~, -COzR~~, -S(O)zR~~ and -CONR~R~~ can be made by standard techniques, for example by reacting a compound of formula (VIII) R4-X-H (VIII) wherein R4 is other than -COR~~, -COzR~~, S(O)ZR~~ and -CONR~R~~ and X is as defined above, with a compound of formula (IX) L-Y-ZNR,Rz (IX) wherein Y, Z, Rl and RZ are as defined above and L represents a hydroxy group or a leaving group such as a halogen. The reaction is typically conducted in the presence of a base at from -78°C to the reflux temperature of the solvent.
The compounds of formulae (VIII) and (IX) are known compounds or may be prepared by analogy with known methods.
Compounds of the invention in which P is -X-U-W- and R4 is -COR~~, -COZR~~, -S(O)zR~~ or -CONR~R~~ can be made in an analogous fashion by reacting a compound of formula (X) R4X-U-L (X) wherein R4, X and U are as defined above and L represents a hydroxy group or a leaving group such as a halogen, with a compound of formula (XI) HWZNR,RZ (XI) wherein W, Z, R, and RZ are as defined above.
The compounds of formula (X) and (XI) are known compounds or may be prepared by analogy with known methods.
Compounds in which P is X or W and R4 is other than -COR", -COZR", -S(O)ZR" and -CONR'R" can be prepared, for example, by reacting a compound of formula (XII) R4-AH (XII) wherein A is -X- or -W-, wherein X and W are as defined above and R4 is other than -COR", -COzR", -S(O)ZR" and -CONR'R", with a compound of formula (XIII) L-Z-NR,RZ (XIII) wherein Z, R, and Rz are as defined above and L is a leaving group such as a triflate group or a halogen atom. The reaction can be conducted under standard conditions. Typically, it takes place in the presence of a base in a solvent such as DMF.
The compounds of formula (XII) are known compounds or may be prepared by analogy with known methods. The compounds of formula (XIII) are also known compounds or may be prepared by analogy with known methods. For example, they can be prepared from a corresponding compound of formula HO-Z-NR,Rz by reaction with triflic anhydride or with PCIs.
Compounds of the invention in which P is X or W and R4 is -COR", -COZR", -S(O)ZR" or CONR'R" can be prepared by reacting a compound of formula (IXV) HA-Z-NR,RZ (IXV) wherein A, Z, Rl and Rz are as defined above, with R4-L, wherein R4 is as defined above and L is a hydroxy group or a leaving group, for example a halogen.
The reaction can be conducted under standard conditions, such as those given above for the reaction of compounds of formulae (VIII) and (IX).
S Compounds of formula (IXV) and compounds of formula R4-L are known compounds or may be prepared by analogy with known methods.
Compounds of the invention in which P is Y, Y is -CO- and R4 is aryl or heteroaryl may be prepared, for example, by a Friedel-Crafts reaction between a compound of formula (XV) R4-H (~) wherein R4 is aryl or heteroaryl, and a compound of formula (XVI) ~NR1R2 (XVI) L VZ
wherein L is a hydroxy group, a group OR wherein R is alkyl, or a halogen, for example chlorine, and Z, V, R, and RZ are as defined above. The reaction can be performed under conventional conditions, in the presence of a catalyst such as A1C13.
Examples of such reactions are described in section 1-15 of "Advanced Organic Chemistry", 3'd Edition, by Jerry March.
The compounds of formulae (XV) and (XVI) are known compounds or may be prepared by analogy with known methods.
Compounds in which P is -Y- or -XY- and in which X, Y and R4 are as defined above may be prepared, for example, by reacting a compound of formula (XVII) Ra~Y~ L
wherein R4 is as defined above, Y~ is -U- or -X-U-, and L is a hydroxy group or a leaving group, for example a halogen atom, with an organometallic compound of formula (XVIII) M-B-NRIRZ (XVIII) wherein B is -V-Z- wherein V and Z are as defined above, R1 and RZ are as defined above and M is a metal-containing moiety such as Li or -MgX wherein X
is a halogen atom such as bromine.
The reaction can be carried out under conventional conditions. Preferably, M
in the formula (XVIII) is Li. When M in the formula (XVIII) is -MgX, it may be necessary to conduct the reaction at around -78 °C and to use a large excess of the compound of formula (XVII).
The compounds of formula (XVII) are known compounds or may be prepared by analogy with known methods. The compounds of formula (XVIII) are also known compounds or may be prepared by analogy with known methods. For example, compounds of formula (XVIII) in which M is Li can be prepared by reacting a corresponding compound of formula Br-B-NR1R2 with lithium or with magnesium.
In some cases, it may be necessary to protect the -NR1R2 group during the synthesis of the compounds of formula (XVIII) or during the reaction between the compounds of formulae (XVIII) and (XVII). This can be done by standard techniques.
Compounds of the invention in which P is -Y-W- or -XYW-, wherein Y is -UV- and -V- is -(C,-C6 alkyl)-, can be made, for example, by reacting a compound of formula (IXX) R4 P-L (IXX) wherein R4 and P are as defined above and L is a leaving group such as a halogen atom or a triflate group, with a compound of formula (XX) S HW-ZNRIRZ (XX) wherein W, Z, R~ and Rz are as defined above. The reaction can be conducted under conventional conditions. Typically, it is conducted in the presence of a base.
If necessary, the NRiR2 group can be protected during the reaction by conventional means.
The compounds of formulae (IXX) and (XX) are knowN compounds, or may be prepared by analogy with known methods. For example, the compounds of formula (IXX) can be prepared by reacting a corresponding compound of formula R4-P-OH with triflic anhydride or PCIs.
1 S Compounds in which P is a direct bond can be prepared by conventional synthetic techniques.
A compound of the invention can, of course, be converted to a different compound of the invention by standard functional group interconversions known to those of skill in the art. For example, a compound of the invention in which U
is -CO- can be converted to a compound of the invention in which U is -C(=NR)- by reaction with a compound of formula RNH2. Suitable such reactions are described in section 6-14 of "Advanced Organic Chemistry" 3~d Edition, by Jerry March.
Pharmaceutically acceptable salts of the compounds of formula (I) may be prepared by salifying a compound of formula (I) with an appropriate acid or base.
The compounds of the invention are activators of sGC. They can be used as selective sGC activators. A compound of the invention can therefore be used as a vasodilator or to inhibit platelet aggregation. It can be used for the treatment or prevention of peripheral vascular diseases such as hypertension, angina pectoris, arteriosclerosis, or for the treatment or prevention of glaucoma, preeclampsia, Raynaud's Syndrome, stroke or erectile dysfunction. Further, the compounds of the invention are effective in improving ocular blood flow. They can therefore be used SUBSTITUTE SHEET (RULE 26) in the treatment and prevention of age-related macular degeneration (AMD). For example, they can be used in the treatment and prevention of non-exudative or exudative AMD. They can also be used in the treatment and prevention of neovascular or non-neovascular AMD.
Conditions attributable to down regulation of sGC can thus be alleviated.
Accordingly, the present invention also provides a compound of formula (I), as defined above, or a pharmaceutically acceptable salt thereof, for use in the treatment of the human or animal body, wherein R,, Rz, Z, R3, Y, X and RQ are as defined above.
The compounds of the invention may be administered in a variety of dosage forms. Thus, they can be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules. The compounds of the invention may also be administered parenterally, either subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques. The compounds may also be administered as suppositories.
A compound of the invention is typically formulated for administration with a pharmaceutically acceptable Garner or diluent. For example, solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents;
e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations.
Such pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tabletting, sugar-coating, or film coating processes.
Liquid dispersions for oral administration may be syrups, emulsions and suspensions. The syrups may contain as. carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.
Suspensions and emulsions may contain as carrier, for example a natural SUBSTITUTE SHEET (RULE 26) gum, agar, sodium alginte, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.
Solutions for intravenous or infusions may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.
A therapeutically effective amount of a compound of the invention is administered to a patient. A typical daily dose is from about 0.1 to 50 mg per kg of body weight, according to the activity of the specific compound, the age, weight and conditions of the subject to be treated , the type and severity of the disease and the frequency and route of administration. Preferably, daily dosage levels are from 5 mg to2g.
The Examples which follow illustrate the invention. , EXAMPLE S
The synthesis of some of the compounds of the invention is detailed below.
Examines 1 to 69 S The aryl acid (different for each reaction) (0.1 mmol), 3-(dimethylamino)-propylamine (10 mg, 0.1 mmol), N, N (diisopropyl)amino-methylpolystyrene resin (PS-DIEA), (86.0 mg, 0.3 mmol, loading 3.5 mmol/g) and O-(7-azabenzotriazol-1-yI)-N, N, N, N tetramethyluronium hexafluorophosphate (HATU) (38 mg, 0.1 mmol) were shaken under nitrogen in anhydrous acetonitrile (4 mL) and heated to 50 °C for S hours. After this time the reaction mixture was cooled to room temperature.
Tetrafluorophthalic anhydride (65 mg, 0.3 mmol) was then added and the reaction mixture was shaken under nitrogen for 18 hours. Macroporous triethylammonium methylpolystyrene carbonate resin (MP-carbonate), (610 mg, 1.96 mmol, loading 3.18 mmol/g) was then added and the reaction mixture was shaken under nitrogen for a further 48 hours. The reactions were then filtered through filter syringes into vials and washed with methanol. The solvent was removed on a vacuum concentrator and each product was weighed and analysed by LC-MS.
This method was used to synthesise the following compounds. The molecular weight, purity and yield of the compounds synthesised is shown in Table 1.
Example No. Compound 1 N-(3-Dimethylamino-propyl)-2-[1-(4-fluorobenzoyl]-benzamide (CFM2262) 2 N-(3-Dimethylamino-propyl)-3-phenoxy-benzamide (CFM2263) 3 N-(3-Dimethylamino-propyl)-2-phenoxy-benzamide (CFM2264) 4 2-(4-Chloro-phenoxy)-N-(3-dimethylamino-propyl)-nicotinamide (CFM2265) 5 4'-n-Propyl-biphenyl-4-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2266) 6 2-[1-(4-Bromo-phenyl)-methanoyl]-cyclohexanecarboxylic acid (3-dimethylamino-propyl)-amide(CFM2267) 7 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2268) 8 2-[1-(4-Chlorobenzoyl]-N-(3-dimethylamino-propyl)-benzamide (CFM2269) 9 2-Phenyl-quinoline-4-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2331) 10 2-[1-(4-Chloro-3-nitrobenzoyl)]-N-(3-dimethylamino-propyl)-benzamide (CFM2332) 11 N-(3-Dimethylamino-propyl)-2-pyren-1-yl-acetamide (CFM2333) 12 N-(3-Dimethylamino-propyl)-2-[1-(3-methyl-benzo[b]thiophen-2-yl)-methanoyl]-benzamide (CFM2320) 13 4-Chloro-N-(3-dimethylamino-propyl)-2-phenoxy-benzamide (CFM2321) 14 N-(3-Dimethylamino-propyl)-3-(4-phenoxy-phenyl)-propionamide (CFM2322) 15 N-(3-Dimethylamino-propyl)-2-[1-(1-trifluoromethyl-1,3,4,9-tetrahydro-b-carbolin-2-yl)-methanoyl]-benzamide (CFM2334) 16 1-(4-Chloro-phenyl)-2,5-dimethyl-1-pyrrole-3-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2335) 17 2- { 1-[(3-Dimethylamino-propylcarbamoyl)-methyl]-cyclopentyl}-N-(4-trifluoromethoxy-phenyl)-acetamide (CFM2336) 18 8-[2-(3-Dimethylamino-propylcarbamoyl)-phenylsulfanyl]-naphthalene-1-carboxylic acid methylamide (CFM2337) 19 3-Methyl-5-(4-methyl-[1,2,3]thiadiazol-5-yl)-1-(4-trifluoromethoxy-phenyl)-1H pyrazole-4-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2338) SUBSTITUTE SHEET (RULE 26) 20 6,8-Di-tert-butyl-4-oxo-4H chromene-2-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2339) 21 2-(Furan-2-yl)-quinoline-4-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2340) 22 Biphenyl-2,2'-dicarboxylic acid 2'-[(3-dimethylamino-propyl)-amide]-2-[(4-fluoro-phenyl)-amide] (CFM2342) 23 3-Phenyl-pentanedioic acid (3-chloro-4-methyl-phenyl)-amide (3-dimethylamino-propyl)-amide (CFM2343) 24 2-(3,4-Dimethoxy-phenyl)-6-methyl-quinoline-4-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2344) 25 6-Bromo-(2-thiophen-3-yl)-quinoline-4-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2345) 26 3-(4-Chloro-phenyl)-4-cyano-S-isobutylsulfanyl-thiophene-2-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2346) 27 4-(4-Chloro-phenoxy)-N-(3-dimethylamino-propyl)-3-nitro-benzamide (CFM2347) 28 6-(2,4-Dichloro-phenyl)-cyclohex-3-ene carboxylic acid (3-dimethylamino-propyl)-amide (CFM2348) 29 N-(3-Dimethylamino-propyl)-2-(2-phenylsulfamoyl-phenylsulfanyl)-benzamide(CFM2349) 30 2'-Fluoro-[1,1'-biphenyl]-4-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2350) 31 2-Benzylsulfanyl-N-(3-dimethylamino-propyl)-benzamide (CFM23 51 ) 32 Pyrazine-2,3-dicarboxylic acid 2-[(3-dimethylamino-propyl)-amide] 3-[(5,6,7,8-tetrahydro-naphthalen-1-yl)-amide]

(CFM2352) 33 2-[(3,5-Dichloro-phenylcarbamoyl)-methylsulfanyl]-N-(3-dimethylamino-propyl)-nicotinamide (CFM2432) SUBSTITUTE SHEET (RULE 26) 34 2-(3-Trifluoromethyl-phenyl)-thiazole-4-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2368) 35 2-(4-Chloro-phenyl)-thiazole-4-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2369) 36 5-Chloro-1-(2,4-dichloro-benzyl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2370) 37 1-(2,4-Dichloro-benzyl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2371) S 38 S-Chloro-1-(3,4-dichloro-benzyl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2372) 39 1-(3,4-Dichloro-benzyl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2373) 40 5-Chloro-1-(2,6-dichloro-benzyl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2388) 41 1,1-Dimethyl-indan-4-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2389) 42 N-(3-Dimethylamino-propyl)-2-[1-(4-ethyl-phenyl)-methanoyl]-benzamide (CFM2390) 43 N-(3-Dimethylamino-propyl)-3-(2,4,5-trimethyl-phenyl)-butyramide (CFM2391 ) 44 2-[3-(3,4-Dichloro-phenyl)-ureidoJ-N-(3-dimethylamino-propyl)-benzamide (CFM2392) 45 N-(3-Dimethylamino-propyl)-4-oxo-2,3,4-triphenyl-butyramide (CFM2393) 46 5-(4-Chloro-phenylsulfanyl)-[1,2,3]thiadiazole-4-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2394) 47 2-(3-Chloro-5-trifluoromethyl-pyridin-2-ylsulfanyl)-3-methyl-3H imidazole-4-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2395) SUBSTITUTE SHEET (RULE 26) 48 2-(2-Chloro-4-trifluoromethyl-phenyl)-[1,3]-thiazole-4-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2396) 49 2-(2,3-Dihydro-1-benzofuran-5-yl)-1,3-thiazole-4-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2397) 50 2-(2,3-Dichloro-phenyl)-1,3-thiazole-4-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2398) 51 4-[4-(4-Chloro-phenyl)-thiazol-2-yl]-N-(3-dimethylamino-propyl)-benzamide (CFM1899) 52 5-(4-Fluoro-phenyl)-thiophene-2-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2399) 53 4-Methyl-2-(3-trifluoromethyl-phenyl)-thiazole-5-carboxylic acid (3-dilnethylamino-propyl)-amide (CFM2400) 54 3-(4-tent-Butyl-benzyloxy)-thiophene-2-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2401 ) 55 4-Oxo-3-(3-trifluoromethyl-phenyl)-3,4-dihydro-phthalazine-1-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2402) 56 2-(4-Chloro-phenyl)-N-(3-dimethylamino-propyl)-4-oxo-4-phenyl-butyramide (CFM2403) 57 5-(4-Chloro-phenyl)-1-phenyl-1H pyrazole-3-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2404) 58 N-(3-Dimethylamino-propyl)-4-(4-phenyl-thiazol-2-yl)-benzamide (CFM2405) 59 1-(2,4,5-Trichloro-phenylsulfonyl)-pyrrolidine-2-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2406) 60 3-(3,4-Dichloro-benzylsulfanyl)-thiophene-2-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2407) 61 5-Chloro-3-phenyl-1H indole-2-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2408) SUBSTITUTE SHEET (RULE 26) 62 N-(3-Dimethylamino-propyl)-2-[1-(4-fluoro-benzyl)-1H
indol-3-yl]-acetamide (CFM2409) 63 2-Phenyl-imidazo[1,2-a]pyridine-3-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2410) 64 N-(3-Dimethylamino-propyl)-2-(7-ethyl-lI~ indol-3-yl)-4-oxo-4-phenyl-butyramide (CFM2411) 65 Phenyl-trifluoromethyl-thieno[3,2-b]pyridine-2-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2412) 66 3-(4-Nitro-3-trifluoromethyl-phenoxy)-thiophene-2-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2428) 67 2-(5-Chloro-1-methyl-3-phenyl-1H pyrazol-4-ylmethylsulfanyl)-N-(3-dimethylamino-propyl)-benzamide (CFM2429) 68 2-(4-Chloro-benzylsulfanyl)-3-methyl-4-oxo-3,4-dihydro-quinazoline-7-carboxylic acid (3-dimethylamino-propyl)-amide (CFM243 0) 69 N-(3-Dimethylamino-propyl)-4-[4-(4-methoxy-phenyl)-pyrimidin-2-ylsulfanylmethyl]-benzamide (CFM2431) SUBSTITUTE SHEET (RULE 26) Table 1 Example Molecular LC-MS Results % Yield % Yield Weight Purity (mg) 1 328.22 62.1 25.5 40 2 298.22 86.6 23.7 41 3 298.22 86.1 32.1 55 4 333.64 96.6 33 51 5 324.3 100 35.1 55 6 395.17 60.1 33.5 43 7 340.18 95.7 14.2 21 g 344.68 58.5 25.2 37 12 380.35 90.5 32.2 43 13 332.67 73.8 24.5 38 14 326.28 96.1 21.2 33 9 333.27 94.0 22.6 35 10 389.68 94.4 43.8 57 11 344.3 44.0 46.1 68 15 472.35 96.2 50.9 >100 16 333.7 87.0 24.3 74 17 429.35 71.6 30.1 71 1 g 421.4 52.4 28.7 69 19 468.34 72.4 28.1 61 20 386.37 68.0 10.8 28 21 323.23 92.9 12.8 40 22 350.1 90.8 22.5 65 23 415.8 52.0 17 41 24 407.35 90.5 15.5 38 25 418.19 69.5 13.1 32 26 435.88 95.9 21.3 43 27 377.67 83.6 12.8 33 2g 355.15 59.0 16.8 48 29 469.46 72.9 21.9 74 30 300.24 93.1 11.5 35 31 328.31 63.4 16 34 32 381.32 57.0 17.1 45 34 357.24 97.3 14.1 40 35 323.68 96.9 17.7 55 36 416.57 94.1 10.1 25I

37 382.13 86.0 14 37 38 416.57 88.9 12.8 31 39 382.13 64.5 10.3 27 40 416.57 100 22.6 55 41 274.24 97.4 12.3 45 42 338.28 89.0 16.7 50 43 290.28 81.6 15.7 55 44 409.15 91.9 12.1 30 45 414.38 41.0 18.8 47 46 356.73 86.6 20.3 58 47 421.71 79.9 14.3 34 48 391.68 90.9 25 72 49 331.27 91.2 24.5 20 50 358.13 34.2 16.3 75 52 306.24 96.4 18.3 44 53 371.26 97.4 27.6 60 54 374.38 94.8 75 55 418.26 96.7 26.2 71 56 372.73 34.4 21 51 57 382.73 100 19.9 54 58 365.34 100 26.3 69 59 442.63 96.6 16.2 45 60 403.23 100 27.8 63 61 355.71 100 19.9 50 62 367.71 100 8.9 25 63 322.25 54.6 26.2 66 64 405.38 97.8 21.2 53 65 407.3 100 11.5 50 66 417.24 79.5 19.7 48 442.85 59.7 5.1 12 68 444.82 32.7 18.9 43 69 436.41 86.3 23.6 55 33 441.22 40.3 18.2 42 Examples 70 to 99 The aryl acid (different for each reaction) (0.1 mmol) was stirred under nitrogen in anhydrous toluene (2 mL) and heated to 50 °C. Triethylamine (10 mg, 0.1 mmol) dissolved in 1 mL of anhydrous toluene was then added. The temperature was raised to 80 °C and diphenylphosphorylazide (DPPA), (27.0 mg, 0.1 mmol) was added.

The reaction was kept at this temperature for 1 hour then cooled to room temperature while still stirnng under nitrogen.
3-(Dimethylamino)-propylamine (10 mg, 0.1 mmol) was added and the whole mixture was stirred at room temperature overnight. Tetrafluorophthalic anhydride (64.7 mg, 0.3 mmol) was added and the reaction stirred for a further 18 hours.
Following this 20 equivalents of macroporous triethylammonium methylpolystyrene carbonate resin (MP-carbonate), (610 mg, 1.96 mmol) was added and the reactions were stirred for another 24 hours. Each reaction was then filtered through filter syringes into vials and washed with methanol. The solvent was removed using a vacuum concentrator and each product was weighed and analysed by LC-MS.
This method was used to synthesise the following compounds. The molecular weight, purity and yield of the compounds synthesised is shown in Table 2.
Examples Compounds No.

70 1-(3-DimethyIamino-propyl)-3-(2-phenoxy-phenyl)-urea (CFM2260) 71 1-[2-(4-Chloro-phenoxy)-pyridin-3-yl]-3-(3-dimethylaminopropyl)-urea (CFM2261 ) 72 1-(3-Dimethylamino-propyl)-3-pyren-1-ylmethyl-urea (CFM2317) 73 1-(3-Dimethylamino-propyl)-3-[(1R,2R)-5-phenyl-2-(1-phenyl-methanoyl)-cyclohexyl]-urea (CFM2318) 74 1-(3-Dimethylamino-propyl)-3-[2-(4-phenoxy-phenyl)-ethyl]-urea (CFM2319) .

75 1-(3-Dimethylamino-propyl)-3-[3-methyl-5-(4-methyl-[ 1,2,3]thiadiazol-5-yl)-1-(4-trifluoromethoxy-phenyl)-1 H-pyrazol-4-yl]-urea (CFM2353) 76 2'-[3-(3-Dimethylamino-propyl)-ureido]-biphenyl-2-carboxylic acid (4-fluoro-phenyl)-amide (CFM2354) 77 N-(3-Chloro-4-methyl-phenyl)-4-[3-(3-dimethylamino-propyl)-ureido]-3-phenyl-butyramide (CFM2355) 78 1-[4-(4-Chloro-phenylsulfanyl)-thiophen-3-yl]-3-(3-dimethylamino-propyl)-urea (CFM2356) 79 1-[2-(3,4-Dimethoxy-phenyl)-6-methyl-quinolin-4-yl]-3-(4-dimethylamino-propyl)-urea (CFM2357) 80 1-(6-Bromo-2-thiophen-3-yl-quinolin-4-yl)-3-(3-dimethylamino-propyl)-urea (CFM2358) 81 1-[3-(4-Chloro-phenyl)-4-cyano-5-isobutylsulfanyl-thiophen-2-yl]-3-(3-dimethylamino-propyl)-urea (CFM2359) 82 1-[6-(2,4-Dichloro-phenyl)-cyclohex-3-enyl]-3-(3-dimethylamino-propyl)-urea (CFM2360) 83 1-(2-Benzylsulfanyl-phenyl)-3-(3-dimethylamino-propyl)-urea (CFM2361 ) 84 2-{2-[3-(3-Dimethylamino-propyl)-ureido]-phenylsulfanyl}-N-phenyl-benzenesulfonamide (CFM2362) 85 1-(3-Dimethylamino-propyl)-3-(2'-fluoro-biphenyl-4-yl)-urea (CFM2363) 86 N-(3,S-Dichloro-phenyl)-2-{3-[3-(3-dimethylamino-propyl)-ureido]-pyridin-2-ylsulfanyl}-acetamide (CFM2364) 87 1-(3-Dimethylamino-propyl)-3- {2-[ 1-( 1-trifluoromethyl-1,3,4,9-tetrahydro-b-carbolin-2-yl)-methanoyl]-phenyl}-urea (CFM2366) 88 8-{2-[3-(3-Dimethylamino-propyl)-ureido]-phenylsulfanyl}-naphthalene-1-carboxylic acid methylamide (CFM2367) 89 1-[ 1-(3,4-Dichloro-benzyl)-6-oxo-1,6-dihydro-pyridin-3-yl]-3-(3-dimethylamino-propyl)-urea (CFM2413) 90 1-(3-Dimethylamino-propyl)-3-(3-oxo-1,2,3-triphenyl-propyl)-urea (CFM2414) 91 1-[5-(4-Chloro-phenyl)-1-(3,4-dichloro-phenyl)-1H
pyrazol-3-yl]-3-(3-dimethylamino-propyl)-urea (CFM241 S) 92 1- {4-[4-(4-Chloro-phenyl)-thiazol-2-yl]-phenyl}
-3-(3-dimethylamino-propyl)-urea (CFM2416) 93 1-(3-Dimethylamino-propyl)-3-[5-(4-fluoro-phenyl)-thiophen-2-yl]-urea (CFM2417) 94 1-[3-(4-tent-Butyl-benzyloxy)-thiophen-2-yl]-3-(3-dimethylamino-propyl)-urea (CFM2418) SUBSTITUTE SHEET (RULE 26) 95 1-(3-Dimethylamino-propyl)-3-[4-(4-phenyl-thiazol-2-yl)-phenyl]-urea (CFM2419) 96 1-[3-(3,4-Dichloro-benzylsulfanyl)-thiophen-2-yl]-3-(3-dimethylamino-propyl)-urea (CFM2420) 97 1-[2-(S-Chloro-1-methyl-3-phenyl-1H pyrazol-4-ylinethylsulfanyl)-phenyl]-3-(3-dimethylamino-propyl)-urea (CFM2433) 98 1-[2-(4-Chloro-benzylsulfanyl)-3-methyl-4-oxo-3,4-dihydro-quinazolin-7-yl]-3-(3-dimethylamino-propyl)-urea (CFM2434) 99 1-(3-Dimethylamino-propyl)-3-{4-[4-(4-methoxy-phenyl)-pyrimidin-2-ylsulfanylmethyl]-phenyl}-urea (CFM2435) Table 2 ExampleMolecular Weight LC-MS Results % Yield % Yield of Product Product (mg) 70 313.22 57.53 51 83.06 71 348.64 56.3 41.4 60.6 72 359.3 58.85 108.7 >100 73 407.38 42.59 75.1 94.1 74 341.28 54.28 52.1 77.9 87 487.35 53.05 29.4 61.44 88 436.4 53.98 63.6 >100 75 483.34 42 41.8 87.45 76 434.34 76.93 26 60.48 77 430.8 31.66 34.5 80.98 78 369.76 74.31 36.3 99.18 79 422.35 26.75 36.7 87.79 80 433.19 69.82 32.4 75.55 81 450.88 32 27.3 61.31 82 370.15 38.84 29.1 79.42 83 343.31 100 32.2 94.46 84 484.46 36.4 15.8 32.94 85 315.21 56.84 23.3 74.68 86 456.22 38.85 58.6 >100 89 397.13 ~ 32.11 46.1 >100 90 429.38 35.0 51.0 >100 91 466.62 51.18 45.7 98.6 92 414.78 70.68 65.8 >100 93 321.24 48.83 20.5 65.12 94 389.38 44.0 41.8 >100 95 380.34 49.46 33.5 89.88 96 418.23 27.0 32.8 80 97 457.85 52.98 47.1 >100 98 459.82 60.47 65.9 >100 99 451.41 55.72 19.9 44.53 Example 100 1-(4-Bromophenyl)-3-(3-(1-pyrrolidinyl) propyl) urea (CFM2138) 4-Nitrophenyl chloroformate (87.0 mg, 0.436 mmol), 4-bromoaniline (50.0 mg, 0.29 mmol) and triethylamine (44.0 mg, 0.436 mmol) were refluxed under nitrogen in SUBSTITUTE SHEET (RULE 26) anhydrous THF (20 mL) for 18 hours. After this time 1-(3-aminopropyl) pyrrolidine (55.O mg, 0.436 mmol) was added and the whole reaction mixture was refluxed for a further 2 hours.
The reaction mixture was cooled to room temperature and tetrafluorophthalic anhydride (191.0 mg, 0.87 mmol) was added. The reaction was stirred at room temperature under nitrogen for 1 hour, then 6 equivalents of tris-(2-aminoethyl)amine polystyrene resin (PS-trisamine), (500 mg, 1.74 mmol, loading 3.5 mmol/g) was added and the reaction stirred for 2 hours. Following this 20 equivalents of Dowex AG1 resin (OH- form) (1.68 g, 5.8 mmol, loading 3.45 mmol/g) was added and the mixture was stirred for 18 hours at room temperature.
It should be noted that the Cl~ form of the resin was converted to the OH-form by washing with 20 volumes of 1M NaOH solution, followed by distilled water until the washings are neutral. Another 20 equivalents of the resin was added after this time and the reaction was stirred for a further 2 hours. The reaction mixture was then filtered and the solvent removed using a vacuum concentrator.
Example 101 1-(4-Bromophenyl)-3-(3-dimethylamino propyl) urea (CFM2134) Prepared as in Example 100 using 4-nitrophenyl chloroformate (77.2 mg, 0.38 mmol), 4-bromoaniline (30.0 mg, 0.174 mmol) and triethylamine (38.8 mg, 0.38 mmol) to form the intermediate followed by 3-(dimethylamino)propylamine (26.6 mg, 0.26 mmol) to form the desired product. Work-up as in Example 100. The crude product was purified by flash chromatography using MeOH/CHC13 (40:60).
Example 102 3-(4-Bromophenyl)-1-methyl-1-(3-dimethylamino propyl) urea (CFM2139) Prepared as in Example 100 using 4-nitrophenyl chloroformate (87.0 mg, 0.436 mmol), 4-bromoaniline (50.0 mg, 0.29 mmol) and triethylamine (44.0 mg, 0.436 mmol) refluxed for 5 hours in anhydrous THF (20mL) to form the intermediate.
Then N,N,N-trimethyl-1,3-propanediamine (50.5 mg, 0.436 mmol) was added and the reaction mixture refluxed for 18 hours to form the title compound. Work-up as in Example 100.
Example 103 1-(3-Phenyl-5-methoxy phenyl)-3-(3-dimethylamino propyl) urea (CFM2148) Prepared as in Example 100 using 4-nitrophenyl chloroformate (45.5 mg, 0.226 mmol), S-phenyl-o-anisidine (30.0 mg, 0.1 S 1 mmol) and triethylamine (22.8 mg, 0.226 mmol) refluxed in anhydrous THF (20 mL) for 18 hours to form the intermediate followed by 3-(dimethylamino)-propylamine (23.1 mg, 0.226 mmol) and refluxed for a further 5 hours to form the title compound. Work-up as in Example 100.
Example 104 3-(4-Chlorophenyl)-1-methyl-1-(3-dimethylamino propyl) urea (CFM2200) Prepared as in Example 100 using 4-nitrophenyl chloroformate (830 mg, 4.12 mmol), 4-chloroaniline (350 mg, 2.75 mmol) and triethylamine (416 mg, 4.12 mmol) refluxed for 7 hours in anhydrous THF (30mL) to form the intermediate. Then N,N,N'-trimethyl-1,3-propanediamine (478 mg, 4.12 mmol) was added and the reaction mixture refluxed for 18 hours to form the title compound. Work-up as in Example 100.
Example 105 1-(3-Nitrophenyl)-1-benzyl-3-(3-dimethylamino propyl) urea (CFM2270) Prepared as in Example 100 using 4-nitrophenyl chloroformate (66.0 mg, 0.328 mmol), N-benzyl-3-nitroaniline (50.0 mg, 0.219 mmol) and triethylamine (33.0 mg, 0.328 mmol) refluxed in anhydrous THF (20 mL) for 6 hours to form the intermediate followed by 3-(dimethylamino)propylamine (44.6 mg, 0.438 mmol) and refluxed for a further 36 hours to form the title compound. Work-up as in Example 100.
Example 106 1-Benzyl-1-(4-methyl-3-pyridinyl)-3-(3-dimethylamino propyl) urea (CFM2271) Prepared as in Example 100 using 4-nitrophenyl chloroformate (76.0 mg, 0.378 mmol), 2-benzylamino-4-methyl-pyridine (50.0 mg, 0.25 mmol) and triethylamine (38.0 mg, 0.378 mmol) refluxed in anhydrous THF (20 mL) for 5 hours to form the intermediate followed by 3-(dimethylamino)propylamine (38.0 mg, 0.378 mmol) and refluxed for a further 18 hours to form the desired product. Work-up as in Example 100. The crude product was purified by flash chromatography using a gradient from to 50 % MeOH (in CHC13) to give the title compound.
10 Example 107 1-Methyl-1-(3,5-bistrifluoromethylphenyl)-3-(3-dimethylaminopropyl)urea (CFM2311) Prepared as in Example 100 using 4-nitrophenyl chloroformate (62.0 mg, 0.308 mmol), N-methyl-3,5-bis(trifluoromethyl)aniline (50.0 mg, 0.206 mmol) and triethylamine (31.0 mg, 0.308 mmol) refluxed in anhydrous THF (20 mL) for 5 hours to form the intermediate followed by 3-(dimethylamino)propylamine (31.5 mg, 0.308 mmol) and refluxed for a further 18 hours to form the desired product. Work-up as in Example 100. The crude product was purified by flash chromatography using a gradient from 10 to 40 % MeOH (in CHC13) to give the title compound.
Example 108 1-(2-Phenacyl-4-chorophenyl)-1-methyl-3-(3-dimethylamino propyl) urea (CFM2310) 4-Nitrophenyl chloroformate (61.5 mg, 0.31 mmol), 5-chloro-2-(methylamino)-benzophenone (50.0 mg, 0.20 mmol) and triethylamine (30.80 mg, 0.31 mmol) were refluxed for 5 hours in anhydrous THF (20 mL) as in Example 100 to form the intermediate. Then 3-(dimethylamino)-propylamine (32.0 mg, 0.31 mmol) was added and the mixture was refluxed for a further 5 hours to form the desired product.
Work-up as in Example 100. The crude product was purified by flash chromatography using a gradient from 10 - 40% MeOH (in CHC13) to give the title compound.
Example 109 1-(2-Chloro-4-trifluoromethylphenyl)-3-(3-dimethylaminopropyl) urea (CFM2421 ) 4-Nitrophenyl chloroformate (77.0 mg, 0.39 mmol), 4-amino-3-chloro-benzotrifluoride (50.0 mg, 0.26 mmol) and triethylamine (38.0 mg, 0.39 mmol) were refluxed for 18 hours in anhydrous THF (20 mL) as in Example 100 to form the intermediate. Then 3-(dimethylamino)-propylamine (38.0 mg, 0.39 mmol) was added and the mixture was refluxed for a further 5 hours to form the desired product.
Work-up as in Example 100. The crude product was purified by flash chromatography using a gradient from 10 - 40% MeOH (in CHC13) to give the title compound.
Example 110 1-(3-Fluoro-5-tri~luoromethylphenyl)-3-(3-dimethylaminopropyl) urea (CFM2422) 4-Nitrophenyl chloroformate (84.0 mg, 4.19 mmol), 3-amino-5-fluorobenzotrifluoride (50.0 mg, 0.28 mmol) and triethylamine (42.0 mg, 4.19 mmol) were refluxed for 18 hours in anhydrous THF (20 mL) as in Example 100 to form the intermediate. Then 3-(dimethylamino)-propylamine (42.0 mg, 4.19 mmol) was added and the mixture was refluxed for a further 5 hours to form the desired product. Work-up as in Example 100. The crude product was purified by flash chromatography using a gradient from 10 - 40% MeOH (in CHC13) to give the title compound.
Example 111 1-(3-N-tert-butoxycarbonyl-benzylamino)-3-(3-dimethylaminopropyl) urea 4-Nitrophenyl chloroformate (3.13 g, 15.54 mmol), 3-amino-1-(N-tert-butoxy-carbonyl)benzylamine (2.30 g, 10.36 mmol) and triethylamine (1.56 g, 15.54 mmol) was refluxed for 18 hours in anhydrous THF (100 mL) as in Example 100 to form the intermediate. Then 3-(dimethylamino)propylamine (1.58 g, 15.54 mmol) was added and the mixture was refluxed for a further 5 hours to form the desired product.
Work-up same as in Example 100. The crude product was purified by flash chromatography using a gradient from 10 - 40% MeOH (in CHCI3) to give the title compound.
Example 112 N-(3-Dimethylamino-propyl)-2-[1-(4-fluorobenzoyl]-benzamide (CFM2262) 2-(4-Fluorobenzoyl)benzoic acid (1.25 g, 5.12 mmol), N,N (diisopropyl)amino-methylpolystyrene resin (PS-DIEA), (4.30 g,15.36 mmol), and O-(7-azabenzotriazol-1-yl)-N,N,N,N tetramethyluronium hexafluorophosphate (HATU) (1.95 g, 5.12 mmol) was stirred in anhydrous acetonitrile (50 mL) at room temperature under nitrogen for 5 minutes. Then 3-(dimethylamino)propylamine (0.52 g, 5.12 mmol) was added and the temperature was taken up to 50 °C and the mixture was left to stir at this temperature for 18 hours. The mixture was allowed to cool and tetrafluorophthalic anhydride (3.40 g, 15.36 mmol) was added and the mixture was allowed to stir for 5 hours. To the mixture was added water (5 mL) and the solvent was removed on a vacuum concentrator.
The crude product was purified by flash chromatography using a gradient from 5 to 10%
MeOH (in CHC13) and the title compound was isolated as a white solid 0.36 g, yield (mp 84 - 85 °C).
Example 113 2-(1-(4-Chlorobenzoyl]-N-(3-dimethylamino-propyl)-benzamide (CFM 2269) 2-(4-Chlorobenzoyl)-benzoic acid (1.25 g, 4.80 mmol), N,N (diisopropyl)amino-methylpolystyrene resin (PS-DIEA), (4.00 g, 14.38 mmol), and O-(7-azabenzotriazol-1-yl)-N,N,N,N tetramethyluronium hexafluorophosphate (HATU) (1.82 g, 4.80 mmol) was stirred in anhydrous acetonitrile (50 mL) at room temperature under nitrogen for 5 minutes. Then 3-(dimethylamino)propylamine (0.50 g, 4.80 mmol) was added and the temperature was taken up to 50 °C
and the mixture was left to stir at this temperature for 18 hours. The mixture was allowed to cool and tetrafluorophthalic anhydride (3.20 g, 14.40 mmol) was added and the mixture was left to stir for 5 hours. The workup and purification was the same as described in Example 112. The title compound was isolated as a white solid 0.68g, 41 % yield (mp 108-110 °C).
Example 114 5-(4-Chloro-phenyl)-1-phenyl-1H pyrazole-3-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2404) 5-(4-Chlorophenyl)-1-phenyl-1H-pyrazole-3-carboxylic acid (1.10 g, 4.09 mmol), N,N (diisopropyl)amino-methylpolystyrene resin (PS-DIEA), (3.40g, 12.27 mmol), and O-(7-azabenzotriazol-1-yl)-N,N,N,N tetramethyluronium hexafluorophosphate (HATU) (1.56 g, 4.09 mmol) was stirred in anhydrous acetonitrile (SO mL) at room temperature under nitrogen for 5 minutes. Then 3-(dimethylamino)propylamine (0.42 g, 4.09 mmol) was added and the temperature was taken up to 50 °C
and the mixture was left to stir at this temperature for 18 hours. The mixture was allowed to cool and tetrafluorophthalic anhydride (2.70 g, 12.27 mmol) was added and the mixture was allowed to stir for 5 hours. ' The workup and purification was the same as described in Example 112. The title compound was isolated as a white solid 0.62g, 44 % yield (mp 165 °C).
Example 115 5-Chloro-3-phenyl-1H indole-2-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2408) 5-Chloro-3-phenyl-1H-indole-2-carboxylic acid (1.00 g, 3.68 mmol), N,N
(diisopropyl)amino-methylpolystyrene resin (PS-DIEA), (3.00 g, 11.04 mmol), and O-(7-azabenzotriazol-1-yl)-N,N,N,N tetramethyluronium hexafluorophosphate (HATU) (1.49 g, 3.68 mmol) was stirred in anhydrous acetonitrile (SO mL) at room temperature under nitrogen for 5 minutes. Then 3-(dimethylamino)propylamine (0.38 g, 3.68 mmol) was added and the temperature was taken up to 50 °C
and the mixture was left to stir at this temperature for 18 hours. The mixture was allowed to cool and tetrafluorophthalic anhydride (2.43 g, 11.00 mmol) was added and the mixture was allowed to stir for 5 hours. The workup and purification was the same as described in Example 112. The title compound was isolated as a white solid 0.24 g, 18.5 % yield (mp 143-144 °C).
Example 116 N-(3-Dimethylamino-propyl)-2-(2-phenylsulfamoyl-phenylsulfanyl)-benzamide(CFM2349) 2-(2-Phenylsulfamoyl-phenylsulfanyl)-benzoic acid (1.10 g, 2.60 mmol), N,N
(diisopropyl)amino-methylpolystyrene resin (PS-DIEA), (2.18g, 7.78 mmol), and O-(7-azabenzotriazol-1-yl)-N,N,N,N tetramethyluronium hexafluorophosphate (HATU) (0.98 g, 2.6 mmol) was stirred in anhydrous acetonitrile (50 mL) at room temperature under nitrogen for 5 minutes. Then 3-(dimethylamino)propylamine (0.26 g, 2.60 mmol) was added and the temperature was taken up to 50 °C and the mixture was left to stir at this temperature for 18 hours. The mixture was allowed to cool and tetrafluorophthalic anhydride (1.70 g, 7.78 mmol) was added and the mixture was allowed to stir for 5 hours. The workup and purification was the same as described in Example 112. The title compound was isolated as a white solid (0.1 g, 9 %), (mp 75-76 °C).
Example 117 2-Benzylsulfanyl-N-(3-dimethylamino-propyl)-benzamide (CFM2351) 2-Benzylsulfanyl-benzoic acid (1.00 g, 4.09 mmol), N,N (diisopropyl)amino-methylpolystyrene resin (PS-DIEA), (3.40 g, 12.27 mmol), and O-(7-azabenzotriazol-1-yl)-N,N,N,N tetramethyluronium hexafluorophosphate (HATU) (1.55 g, 4.09 mmol) was stirred in anhydrous acetonitrile (50 mL) at room temperature under nitrogen for 5 minutes. Then 3-(dimethylamino)propylamine (0.42 g, 4.09 mmol) was added and the temperature was taken up to 50 °C
and the mixture was left to stir at this temperature for 18 hours. The mixture was allowed to cool and tetrafluorophthalic anhydride (2.60 g, 12.27 mmol) was added and the mixture was allowed to stir for 5 hours. The workup and purification was the same as described in Example 112. The title compound was isolated as a white solid 0.41 g, 30.5 % yield (mp 85-86 °C).
Example 118 6,8-Di-tert-butyl-4-oxo-4H chromene-2-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2339) 6,8-Di-tert-butyl-4-oxo-4H-chromene-2-carboxylic acid (1.00 g, 3.31 mmol), N,N
(diisopropyl)amino-methylpolystyrene resin (PS-DIEA), (2.78 g, 9.93 mmol), and O-(7-azabenzotriazol-1-yl)-N,N,N,N tetramethyluronium hexafluorophosphate (HATU) (1.25 g, 3.31 mmol) was stirred in anhydrous acetonitrile (50 mL) at room temperature under nitrogen for 5 minutes. Then 3-(dimethylamino)propylamine (0.34 g, 3.31 mmol) was added and the temperature was taken up to 50 °C
and the mixture was left to stir at this temperature for 18 hours. The mixture was allowed to cool and tetrafluorophthalic anhydride (2.18 g, 9.93 mmol) was added and the mixture was allowed to stir for 5 hours. The workup and purification was the same as described in Example 112. The title compound was isolated as a white solid (0.26g) in 20 % yield (mp 135-136 °C).
Example 119 3-(4-Chloro-phenyl)-4-cyano-5-isobutylsulfanyl-thiophene-2-carboxylic acid (3-dimethylamino-propyl)-amide (CFM2346) 3-(4-Chlorophenyl)-4-cyano-S-isobutylsulfanyl-thiophene-2-carboxylic acid (1.00 g, 2.84 mmol), N,N (diisopropyl)amino-methylpolystyrene resin (PS-DIEA), (2.37 g, 8.53 mmol), and O-(7-azabenzotriazol-1-yl)-N,N,N,N tetramethyluronium hexafluorophosphate (HATU) (1.08g, 2.84 mmol) was stirred in anhydrous acetonitrile (50 mL) at room temperature under nitrogen for 5 minutes. Then 3-(dimethylamino)propylamine (0.3 g, 2.84 mmol) was added and the temperature was taken up to 50 °C and the mixture was left to stir at this temperature for 18 hours.
The mixture was allowed to cool and tetrafluorophthalic anhydride (1.87 g, 8.52 mmol) was added and the mixture was allowed to stir for 5 hours. The workup and purification was the same as described in Example 112. The title compound was isolated as a white oil/solid 0.3 g, 24 % yield.
Example 120 4-(4-Chloro-phenoxy)-N-(3-dimethylamino-propyl)-3-vitro-benzamide (CFM2347) 4--(4-Chlorophenoxy)-3-vitro-benzoic acid (1.00 g, 3.40 mmol), N, N
(diisopropyl)amino-methylpolystyrene resin (PS-DIEA), (2.84 g, 10.20 mmol), and O-(7-azabenzotriazol-1-yl)-N,N,N,N tetramethyluronium hexafluorophosphate (HATU) (1.29 g, 3.40 mmol) was stirred in anhydrous acetonitrile (50 mL) at room temperature under nitrogen for 5 minutes. Then 3-(dimethylamino)propylamine (0.35 g, 3.40 mmol) was added and the temperature was taken up to 50 °C
and the mixture was left to stir at this temperature for 18 hours. The mixture was allowed to cool and tetrafluorophthalic anhydride (2.24 g, 10.20 mmol) was added and the mixture was allowed to stir for 5 hours. The workup and purification was the same as described in Example 112. The title compound was isolated as a yellow solid (0.6 g) in 46.5% yield (mp 165-167 °C.
Example 121 N-(3-Dimethylamino-propyl)-4-(4-phenyl-thiazol-2-yl)-benzamide (CFM2405) 4-(4-Phenyl-thiazol-2-yl)-benzoic acid (1.38 g, 4.91 mmol), N,N
(diisopropyl)amino-methylpolystyrene resin (PS-DIEA), (3.84 g, 14.70 mmol), and O-(7-azabenzotriazol-1-yl)-N,N,N,N tetramethyluronium hexafluorophosphate (HATU) (1.87 g, 4.91 mmol) was stirred in anhydrous acetonitrile (SO mL) at room temperature under nitrogen for 5 minutes. Then 3-(dimethylamino)propylamine (0.50 g, 4.91 mmol) was added and the temperature was taken up to 50 °C
and the mixture was left to stir at this temperature for 18 hours. The mixture was allowed to cool and tetrafluorophthalic anhydride (3.24 g, 14.70 mmol) was added and the mixture was allowed to stir for 5 hours. The workup and purification was the same as described in Example 112. The title compound was isolated as a white solid (1.18 g) in 66% yield (mp 204-205 °C).

Example 122 1-(3-Dimethylamino-propyl)-3-(2-phenoxyphenyl)-urea (CFM2260) 2-Phenoxybenzoic acid (1.50 g, 7.00 mmol) was stirred in anhydrous toluene (50 mL) at 50 °C under nitrogen. To this mixture was added triethylamine (0.71 g, 7.00 mmol) and the temperature was increased to 80 °C at which stage diphenylphosphorylazide (DPPA) (1.92 g, 7.00 mmol) was added and the mixture was left to stir at this temperature for 5 hours. After this period 3-(dimethylamino)propylamine (0.71 g, 7.00 mmol) was added and the mixture was left to stir at 80 °C overnight under nitrogen. The solvent was removed on a vacuum concentrator The residue was taken up in chloroform (100 mL) and washed with sodium hydroxide (2 x 50 mL). The organic fraction was washed with saturated sodium chloride solution and then dried (NazS04). The solvent was removed on a vacuum concentrator. The crude product was purified by flash chromatography using a gradient from 5 to 10% MeOH (in CHC13) and the title compound was isolated as a white solid (1.00 g ) in 46% yield (mp 126- 128 °C).
Example 123 1-[4-(4-Chloro-phenylsulfanyl)-thiophen-3-yl]-3-(3-dimethylamino-propyl)-urea (CFM2356) 4-(4-Chlorophenylsulfanyl)-thiophene-3-carboxylic acid (1.30 g, 4.80 mmol) was stirred in anhydrous toluene (50 mL) at 50 °C under nitrogen. To this mixture was added triethylamine (0.48 g, 4.80 mmol) and the temperature was increased to 80 °C
at which stage diphenylphosphorylazide (DPPA) (1.32 g, 4.80 mmol) was added and the mixture was left to stir at this temperature for 5 hours. After this period 3-(dimethylamino)propylamine (0.48 g, 4.80 mmol) was added and the mixture was left to stir at 80 °C overnight under nitrogen. The solvent was removed on a vacuum concentrator. The residue was taken up in chloroform (100 mL) and washed with 1M sodium hydroxide (2 x 50 mL). The organic fraction was washed with saturated sodium chloride solution and then dried (Na2S04). The solvent was removed on a vacuum concentrator. The crude product was purified by flash chromatography using a gradient from 5 to 10% MeOH (in CHCl3) and the title compound was isolated as a white solid (0.50 g ) in 28% yield (mp 125-126 °C).
Example 124 1-(3-Dimethylamino-propyl)-3-(2'-fluoro-biphenyl-4-yl)-urea (CFM2363) 2-Fluoro-biphenyl-4-carboxylic acid (1.00 g, 4.63 mmol) was stirred in anhydrous toluene (50 mL) at 50 °C under nitrogen. To this mixture was added triethylamine (0.47 g, 4.63 mmol) and the temperature was increased to 80 °C at which stage diphenylphosphorylazide (DPPA) (1.27 g, 4.63 mmol) was added and the mixture was left to stir at this temperature for 5 hours. After this period 3-(dimethylamino)propylamine (0.48 g, 4.63 mmol) was added and the mixture was left to stir at 80 °C overnight under nitrogen. The solvent was removed on a vacuum concentrator. The residue was taken up in chloroform (100 mL) and washed with' 1M sodium hydroxide (2 x 50 mL). The organic fraction was washed with saturated sodium chloride solution and then dried (Na2S04). The solvent was removed on a vacuum concentrator. The crude product was purified by flash chromatography using a gradient from S to 10% MeOH (in CHCl3) and the title compound was isolated as a orange oil (0.50 g ) in 34% yield.
Physical data for some of the compounds synthesised in the Examples is given in Table 3.

TABLE 3: Physical Data Example 'H NMR 8, CDC13, 300 MHz MS mp yield 101 7.28 (d, 2H, J= 8.7 Hz), 7.17(APCI) 73%
(d, 2H, J= 9.0 Hz), 302 3.22 (q, 2H, J= 5.9 Hz), 2.31[M+2H]' (t, 2H, J= 6.2 Hz), 2.12 (s, 6H), 1.58 (quintet, 2H, J= 6.2 Hz) 100 7.31 - 7.27 (m, 2H), 7.16 - 7.19 (m, 2H), 3.26 (q, (APCI) 69%

2H, J = 6.0 Hz), 2.52 (t, [M+2H]+
2H, J = 6.4 Hz), 2.46 -2.44 (m, 4H); 1.72 - 1.68 (m, 4H), 1.64 (t, 2H, J

= 6.2 Hz) 102 CD30D 7.37 (d, 2H, J= 9.0 (FAB) 314 85%
Hz), 7.29 (d, 2H, J= M+

8.7 Hz), 3.41 (t, 2H, J =
6.4 Hz), 2.95 (s, 3H), 2.37 (t, 2H, J = 6.9 Hz), 2.29 (s, 6H), 1.81 (quintet, 2H, J= 6.7 Hz) 103 8.31 (d, IH, J= 2.26 Hz), (FAB) 328 85%
7.62, (t, 2H, J= 7.16 Hz), 7.41 (t, 2H, J = 6.41 [M+1H]+
Hz), 7.33 - 7.29 (m, 1 H), 7.25 (dd, 1 H, J = 2.5 Hz, J = 8.5 Hz), 6.94 (d, 1 H, J = 8.67 Hz), 3.92 (s, 3H), 3.40 (q, 2H, J

= 5.9 Hz), 2.39 (q, 2H, J=
6.7 Hz), 2.18 (s, 6H), 1.74 - 1.65 (m, 2H) 104 9.86 (br s, IH), 7.26 (d, (FAB) 270 31%
2H, J= 9.0 Hz), 7.12 (d, 2H, J= 9.0 Hz), 3.31 (t, 2H, [M+1H]+
J= 5.8 Hz), 2.83 (s, 3H), 2.32 (t, 2H, J= 5.8 Hz), 2.22 (s, 6H), 1.69 (quintet, 2H, J= 5.8 Hz) 105 8.04 - 8.00 (m, 1H), 7.95 (EI) 356 26%
- 7.91 (m, IH), 7.45 - M+

7.35 (m, 2H), 7.25 - 7.I4 (m, 5H), 6.49 (br s, IH), 4.85 (s, 2H), 3.29 (m, 2H), 2.24 (t, 2H, J = 5.7 Hz), 1.81 (s, 6H), 1.54 (q, 2H, J= 5.7 Hz) IO 106 acetone-d~ 8.42 (d, 1H, J= (APCI) 37%
4.9 Hz), 7.53 - 7.41 327 (m, 5H), 7.16 (s, 1H), 7.06 [M+1H]+
(d, 1H, J= 5.3 Hz), 5.48 (s, 2H), 3.68 (m, 2H), 3.04 (brs, 2H), 2.76 (s, 6H), 2.45 (s, 3H), 2.19 (m, 2H) 108 7.43 (d, 1H, J= 2.26 Hz), (APCI) 30%
7.31 - 7.15 (m, 7H), 374 6.72 (d, IH, J= 9.05 Hz), [M+1H]+
3.76 - 3.69 (m, 1H), 3.32 (s, 3H), 3.33 - 3.30 (m, 1H), 2.60 - 2.40 (m, 2H), 2.19 (brs, 6H), 1.78 - 1.63 (m, 2H) 107 7.68 (s, 2H), 7.63 (s, 1H), (APCI) 33%
6.77 (br s, 1H), 3.35 - 372 3.31 (m, 2H), 3.28 (s, 3H), [M+1H]+
2.64 - 2.52 (m, 2H), 2.23 (br s, 6H), I.80 - I.68 (m, 2H) 111 7.47 - 7.43 (m,2H), 7.35 (t, (FAB) 351 83%
1H, J= 7.9Hz), 7.06 (d, 1H, J= 7.53 Hz), 4.38 [M+1H]+
(d, 2H, J= 5.27 Hz), 4.05 - 3.85 (br s, 3H), 3.50 - 3.40 (m, 2H), 2.80 (t, 2H, J= 6.6 Hz), 2.56 (s, 6H), 1.92 (t, 2H, J=

6.2 Hz), 1.59 (s, 9H) 109 8.36 (d, 1H, J= 8.67 Hz), (EI) 323 24%
7.69 (s, 1H), 7.53 (d, M+

IH, J= 8.29 Hz), 3.08 (t, 2H, J= 7.73 Hz), 2.80 (s, 6H), 1.94 (2H, t, J= 7.35 Hz), 1.31 (t, 2H, J = 7.16 Hz) 110 7.56 (br s, 1H), 7.51 (br (FAB) 308 35%
s, 1H), 6.97 (br d, 1H, J

= 8.29 Hz), 3.26 (t, 2H, J= [M+IH]+
6.78 Hz), 2.62 (t, 2H, J= 7.73 Hz), 2.44 (s, 6H), 1.79 (t, 2H, J=

7.53 Hz) 112 7.81 (d, IH, J = 6.41 Hz), EI 328 84- 44%
7.64 - 7.52 (m, 2H), [M]+

7.48 - 7.39 (m, 2H), 7.29 85C
(d, 1H, J = 6.78 Hz), 7.10 (t, 2H, J = 8.86 Hz), 3.65 - 3.56 (m, 1H), 3.21 - 3.11(m, 1H), 2.92 (t, 2H, J = 7.54 Hz), 2.69(s, 6H), 1.93 - 1.76 (m, 2H) 113 7.81 (d, 1H, J= 6.78 Hz), (APCI) 108- 41%
7.63 - 7.52 (m, 2H), 345 7.38 (s, 4H), 7.29 (d, 1H, [M]+ I 10C
J= 6.78 Hz), 3.65 - 3.56 (quintet, 1H, J= 7.06 Hz), 3.20 - 3.10 (quintet, 1H, J= 7.06 Hz), 2.92 (t, 2H, J= 7.35 Hz), 2.68 (s, 6H), 1.93 - 1.77 (m, 2H) 114 7.45 - 7.43 (m, 3H), 7.37 (APCI) 165C 44%
- 7.32 (m, 3H), 7.23 (d, 383 M+

2H, J = 8.67, Hz), 7.02 (s, 1 H), 3.50 (t, 2H, J =

6.40 Hz), 3.20 (t, 2H, J=
7.73, Hz), 2.91 (s, 6H), 2.08 - 1.99 (quintet, 2H, J = 7.25 Hz) 115 7.57 - 7.38 (m, 7H), 7.22 (FAB) 356 143- 18.5 (dd, 1H, J = 8.67 Hz, J

= 1.89 Hz), 3.29 (t, 2H, J= [M]+ 144C
6.78 Hz), 2.19 (t, 2H, J= 7.53 Hz), 2.16 (s, 6H), 1.60 (quintet, 2H, J=

7.25 Hz) $ 116 8.02 (dd, 1H, J= 7.73 Hz, (APCI) 75- 9%
J= 1.7 Hz), 7.50 (dd, 470 1 H, J = 7.54 Hz, J = 1.51 [M]+ 76C
Hz), 7.41 - 7.11 (m, 9H), 7.01 (t, 2H, J = 6.97 Hz), 3.36 (t, 2H, J =

6.78 Hz), 2.42 (t, 2H, J =
7.91 Hz), 2.21 (s, 6H), 1.74 (quintet, 2H, J= 7.25 Hz) 117 7.43 - 7.20 (m, 9H), 4.16 (APCI) 85- 30.5 (s, 2H), 3.36 (t, 2H, J= 329 M+

6.78 Hz), 2.45 (t, 2H, J =
7.73 Hz), 86C
2.23 (s, 6H), 1.79 (quintet, 2H, J= 7.35 Hz) 118 8.05 (d, 1H, J = 2.64 Hz), (APCI) 135- 20%
7.89 (d, 1H, J= 2.26 387 Hz), 7.88 (s, 1H), 3.47 (t, [M]+ 136C
2H, J= 6.78 Hz), 2.44 (t, 2H, J = 7.72 Hz), 2.27 (s, 6H), 1.84 (quintet, 2H, J= 7.34 Hz), 1.57 (s, 9H), 1.39 (s, 9H) 119 7.54 (d, 2H, J = 8.66 Hz), (APCI) 24%
7.45 (d, 2H, J = 8.67 436 Hz), 3.20 (t, 2H, J = 6.79 [M]+
Hz), 3.07 (d, 2H, J =

7.15 Hz), 2.17 (s, 3H), 2.,14 (t, 2H, J = 7.92 Hz), 2.05 - 1.92 (m, 1H), 1.56 (quintet, 2H, J = 7.44 Hz), 1.09 (d, 6H, J = 6.78 Hz) 120 (CDCl3) 8.50 (d, 1H, J = 2.26(APCI) mp 46.5 Hz), 8.08 (dd, J 378 = 8.66 Hz, J= 2.26 Hz), 7.31 [M]+ 165-(d, 2H, J= 9.04 Hz), 6.96 (d, 2H, J= 8.66 167C
Hz), 6.91 (s, 1H), 3.56 (q, 2H, J= 5.91 Hz), 3.07 (t, 2H, J= 6.60 Hz), 2.79 (s, 6H), 2.11 (quintet, 2H, J= 6.03 Hz) 121 8.16 (d, 2H, J= 8.67 Hz), (APCI) mp 66%
8.04 (d, 2H, J= 7.16 366 Hz ), 7.97 (d, 2H, J= 8.67 [M] 204-Hz), 7.90 (s, 1H), 7.46 (t, 2H, J= 7.35 Hz), 205C
7.37 (d, 1H, J= 7.53 Hz), 3.50 (t, 2H, J= 6.78 Hz), 3.03 (t, 2H, J=

7.54 Hz), 2,77 (s, 6H), 2.00 (quintet, 2H, J=

7.07 Hz) 122 8.06 (dd, 1H, J= 8.11 Hz, (FAB) 314 mp 44%
J= 1.7 Hz), 7.34 (t, (M

2H, J= 8.11 Hz), 7.12 - 7.05 + H)+ 126-(m, 2H), 6.98 -6.91 (m, 3H), 6.82 (dd, 1H, 128C
J= 8.29 Hz, J=

1.51 Hz), 3.19 (t, 2H, J =
6.78 Hz), 2.26 (s, 6H), 1.73 - 1.63 (quintet, 2H, J = 7.25 Hz) SUBSTITUTE SHEET (RULE 26) 123 7.72 (d, 2H, J= 3.39 Hz), (FAB) 370 mp 28%
7.57 (d, 2H, J= 3.76 M+

Hz), 7.24 (d, 2H, J= 8.66 125-Hz), 6.99 (d, 2H, J=

8.67 Hz), 3.16 (t, 2H, J= 126C
6.59 Hz), 2.32 (t, 2H, J= 7.72 Hz), 2.22 (s, 6H), 1.64 (quintet, 2H, J=

7.25 Hz) 124 7.44 (bs, 4H), 7.31 - 7.11 (APCI) 35-(m, 4H), 3.25 (t, 2H, J 316 = 6.78 Hz), 2.44 (t, 2H, J= [M+1H]+ 4%
7.72 Hz), 2.29 (s, 6H), 1.79 - I.69 (quintet, 2H, J= 7.25 Hz) Activity Example 1 Compounds of the invention were assayed to determine their ability to activate sGC. The assay employed was an enzyme immunoassay to measure changes in cGMP. To perform the assay recombinant soluble Guanylate cyclase was added to 1.1 mg/ml IBMX, 2.6 mg/ml GTP, 667 nM DeaNO and the test compound (10~M).
The mixture was then incubated at room temperature for 10 minutes. Compounds were formulated in DMSO diluted in Tris HCl (pH 7.4) buffer and with a final DMSO concentration of <0.5%.
To determine the amount of cGMP produced, the BiotrakTM cGMP enzyme immunoassay system commercially available from AmershamTM was used.
The assay is based on the competition between unlabelled cGMP and a fixed quantity of peroxidase labelled cGMP for a limited amount of cGMP specific antibody. The peroxidase ligand that is bound to the antibody is immobilised on precoated microtitre wells. The amount of labelled cGMP is determind using a one pot stabilised substrate. The concentration of unlabelled cGMP in a sample is determined by interpolation from a standard curve.
The results are shown in Tables 4 to 7. The results shown in Tables 6 and 7 relate to commercially available compounds.
Activi , Example 2 The ability of the compounds of the invention to inhibit platelet aggregation was also determined. ICSO values were measured as set out below.
Materials Prostacyclin (PGIz ; ICN Pharmaceuticals, Oxford) in Tris (O.OSM, pH 9), Sodium citrate solution, Tyrodes solution without calcium (140mM NaCI; 3mM
KCI; l2mM NaHC03; 0.4mM NaHZP04.H20; 2mM MgC12.6H20; 0.1% Glucose) contains O.OSM Hepes, pH7.4. Collagen (collagenreagent Horm, Nycomed S Arzneimittel GmbH, Munchen).
PGIZ dissolved in Tris buffer (O.OSM, pH9). Test compounds dissolved in DMSO (at lOmM) and subsequent dilutions made in Tyrodes; final assay concentration of DMSO did not exceed 0.1% (which is without effect on platelet reactivity).
Platelet Preparation Platelets prepared according to Vagas, J.R., Radomski, M. and Moncada, S.
The use of prostacyclin in the separation from plasma and washing of human 1 S platelets. PROSTAGLANDINS 1982; 23:6:929-945.
Briefly, fresh human blood was collected into tubes contaiung 1:9 sodium citrate (3.I5%) and centrifuged immediately at 260g for 20 minutes to separate the red cells from the platelet rich plasma (PRP). The PRP was decanted and PGIZ
(0.3 ~g/mI) was added. The PRP was then centrifuged at 180g for 1 Omins to sediment the remaining red and white cells. The resulting PRP was decanted into new tubes, PGIZ (0.15~g/ml) added and centrifuged at 950 g for 10 mins to sediment the platelets. The resultant platelet poor plasma (PPP) was discarded and the platelet pellet was resuspended in an equal volume of Tyrodes buffer by gently pipetting up and down. The suspension was centrifuged at 870 g for l Omins at 4 °C.
The supernatant was discarded and the platelet pellet was resuspended in an equal volume of Tyrodes buffer as before. The platelets were counted (using a Coulter Counter model T540 (address)) and normalised to 250,OOOcells/pl using Tyrodes. The resultant suspension was placed on ice for approximately 1 hour until use.
Platelet Assays Platelet aggregation was monitored using either a Chrono-Log model 560-CA
dual channel ormodel 570-4S four channel aggregometer (Chrono-Log Corp., Havertown, PA). Aggregation was analysed by using 0.5 mL aliquots of the platelet suspension at 37 °C using % light transmittance.
For each sample, baseline reading was established for a 3 min period, followed by addition oftest compound or buffer. An ECso dose of collagen was added 1 min later and the response measured 3 min after addition of collagen.
Data Analysis The amplitude of each aggregatory response, normalised to the collagen control, was used to plot dose-response curves. The concentration of drug that inhibited collagen-induced platelet aggregation by SO% (ICS) was calculated from the dose-response curves.
The results are shown in Tables 4 to 7. The results shown in Tables 6 and 7 relate to commercially available compounds.

Table 4 ICSO for Inhibition 1 st Test cGMP. Change with of xample I ~.M cpd (NO Platelet Aggregation Donor Present), % of DEANO response(~M) 70 153.79 4 71 136.37 10+

72 135.49 73 143.35 74 158.0 75 163.88 10+

76 303.25 6 77 284.9 8 78 303.77 4 79 218.24 I O+

80 244.87 6.5 81 230.49 4.5 82 224.57 83 314.64 6 84 408.17 3.5 85 358.65 2 86 358.65 10+

87 336.16 10+

88 377.13 10+

89 10+

91 2.5 94 10+

95 10+

96 10+

97 9.5 98 IO+

101 199.21 100 135.7 102 273.17 103 ~ __ _ 8 ICSO for Inhibition 1 st Test cGMP Change with 1 of xample p,M cpd (NO Platelet Aggregation Donor Present), % of DEANO response(pM) 105 181.53 106 137.91 108 129.29 107 125.26 111 476.39 10+

110 10+

Table 5 ICSO for Inhibition 1st Test cGMP Change with 1mM of Platelet xample cpd (NO Aggregation Donor Present), % of DEANO response(pM) 1 93.33 3.5 2 145.84 6 3 132.77 10+

4 ~ 184.86 7 5 134.99 5 6 131.66 8 7 178.03 8 125.15 2 12 128.76 13 169.14 14 166.45 9 153.88 10+

I O 157.53 6 11 174.75 6 15 201.95 6 16 282.88 6.5 17 173.64 6 18 201.95 10+

19 209.14 10+

20 459.96 5 21 250.98 10+

22 186.32 23 225.46 24 249.76 25 142.96 26 299.44 1.5 27 338.6 6 28 144.71 29 256.76 3.5 30 201.33 31 353.4 1.5 ICso for Inhibition 1 st Test cGMP Change with 1mM of Platelet xample cpd (NO Aggregation Donor Present), % of DEANO response(pM) 32 151.68 10+

34 322.81 6 35 363.36 10+

36 296.59 10+

37 337.89 10+

38 295.16 10+

39 312.4 10+

40 418.37 10+

41 455.13 10+

42 181.88 8 43 215.41 10+

44 457.39 10+

45 218.66 5 46 10+

47 10+

48 10+

49 10+

50 10+

52 10+
56 6.5 59 10+
60 7.5 61 1.5 63 9.5 64 10+
65 10+

Table 6 Compound 1 st Test ICSO for cGMP

Change with ~ibition 1 ~M of cpd (NO DonorPlatelet Present), Aggregation % of DEANO response(~.M) 1-(4-chlorobenzyl)-3-(2-N,N- 156.75 dimethylethylamido)-6-pyridone (CFM1882) 1-(2,6-dichlorobenzyl)-3-(3-N,N- 421.09 20 dimethylpropylamido)-6-pyridone (CFM1883) 1-(3-trifluoromethylbenzyl)-3-(2-N,N-207.03 dimethylethylamido)-2-pyridone (CFM1884) 1-(2,6-dichlorobenzyl)-3-(2-N,N- 194.38 dimethylethylamido)-2-pyridone (CFM1885) 1-(3,4-dichlorobenzyl)-3-(N-[2,N,N- 204.61 dimethylaminoethylamido])-2-pyridone (CFM1886) 1-(2,6-dichlorobenzyl)-3-(N-[2-N,N- 154.78 dimethylaminoethylamido])-6-pyridone (CFM 1887) 5-chloro-1-(3,4-dichlorobenzyl)-3-(2-N,N-140.94 dimethylaminoethylamido)-6-pyridone (CFM 1888) 5-chloro-3-(2-N,N-dimethylaminoethylamido)-1-135.6 (3-trifluoromethylbenzyl)-6-pyridone (CFM1889) 5-chloro-1-(3,4-dichlorobenzyl)-3-N-(2-[N',N'-202.02 dimethylaminoethylamido])-2-pyridone (CFM1890) 5-chloro-1-(4-chlorobenzyl)-3-N-(2-(N',N'-170.53 dimethylamino)ethyl)amido-2-pyridone (CFM 1891 ) 5-chloro-1-(3-trifluoromethylbenzyl)-3-N-164.85 (2-(N',N'-dimethylamino)ethyl)amido-2-pyridone (CFM1892) Compound 1 st Test ICso for cGMP

Change with b~ibition 1 ~M of cpd (NO DonorPlatelet Present), Aggregation % of DEANO response(p,M) 1-benzyl-5-chloro-3-N-(2-[N',N'-dimethylamino]148.43 ethyl)carboxamido-6-pyridone (CFM1893) 5-chloro-1-(4-chlorobenzyl)-3-N-(2-[N',N'-144.32 dimethylamino] ethyl)carboxamido-6-pyridone (CFM1894) 4-(2,4-dichlorobenzoyl)pyrrole-2-N-360.01 dimethylaminopropylcarboxamide (CFM1985) 4-[(N-[3-(N',N'-dimethylaminopropyl)]334.25 10 carboxamido]-2-phenylthiazole (CFM1896) 4-(N-(3-N',N'-dimethylaminopropyl) 296.23 carboxamido)-2-(4-pyridinyl)thiazole (CFM1897) 2-[4-(N-[3-N',N'-dimethylaminopropyl]269.18 1.5 carboxamido)phenyl-4-(3-trifluoromethylphenyl]

thiazole (CF1898) 4-(4-chlorophenyl)-2-(4-[3-N',N'- 233.13 1.5 dimethylaminopropyl]carboxamido)phenyl) 1-(3,5-bis(trifluoromethyl)benzyl)-3-[N-(2-149.33 dimethylaminoethyl)carboxamido]-2 [ 1 H]-pyridone (CFM 1900) N-(3-dimethylaminopropyl)-4-(3-chloro-5-191.9 trifluoromethyl-2-pyridyloxy)phenylsulfonamide (CFM 1901 ) N1-[3-(dimethylamino)propyl]-3-[3-chloro-5-309.73 (trifluoromethyl)-2-pyridyl]propanamide (CFM1902) 3-(N-(2-dimethylaminoethyl)carboxamido]-1-169.35 (4-trifluoromethylbenzyl))-2 [ 1 H]-pyridone (CFM1905) 1-ethyl-3-(3-dimethylaminopropyl)urea266.6 (CFM1917) Compound 1 st Test ICso for cGMP

Change with In~bition 1 ~M of cpd (NO DonorPlatelet Present), Aggregation % of DEANO response(~,M) 1-(3-(dimethylamino)-propyl)-3-phenylurea281.16 (CFM1918) N1-[2-(2,4-dichlorophenoxy)phenylJ-N2-[3-207.01 (dimethylamino)propylJethanediamide (CFM1935) N4-[3-(dimethylamino)propylJ-3-(2,6-142.14 dichlorophenyl)-5-methylisoxazole-4-carboxamide (CFM1936) N-[[3-(2,6-dichlorophenyl)-5-methylisoxazol-4334.47 -ylJcarbonylJ-N'-[3-(dimethylamino)propyl]urea (CFM l 93 7) N-(4-chlorophenyl)-N'-[3-dimethylaminopropylJ299.26 urea (CFM1938) Table 7 1 st Test cGMP

Change with 1 mM

Compound cpd (NO Donor Present), %
of DEANO response N-(3,5-Dichloro-phenyl)-3-(3-dimethylamino-propylamino)p174.42 ropionamide [3-(2-Ethyl-6-methyl-pyridin-3-yloxy)-propyl]-dimethyl188.03 -amine 8-(3-Dimethylamino-propoxy)-1,3,7-trimethyl-3,7-dihydro191.65 -purine-2,6-dione 2-(3-Dimethylamino-propylamino)-isophthalonitrile213.04 Dimethyl amino-(3-methyl-benzo [b] thiophen-2-yl)-propan-1279.3 3 -one (HCl) N-B enzo [ 1,3 ]dioxo 1-5-ylmethyl-N,N-dimethyl-propane-1,3184.90 -di amine N,N-Dimethyl-N-(5-nitro-quinolin-8-yl)-propane-1,3219.03 -diamine 1-(4-Chloro-phenyl)-3-(3-dimethylamino-propyl)-urea421.21 2-Amino-N-(3-dimethylamino-propyl)-benzamide363.98 3-Phenyl-acrylic acid 3-dimethylamino-propyl298.89 ester 3,5-Dinitro-benzoic acid 2-dimethylamino-ethyl141.22 ester [4-(4-Bromo-phenyl)-3-(3-dimethylamino-propyl)-3204.10 H-thiazol -2-ylidene]-phenyl-amine 3-Methyl-benzofuran-2-carboxylic acid dimethylamino197.46 -dimethyl-propyl ester N'-(2-Chloro-4-vitro-phenyl)-N,N-dimethyl-propane-1,3161.70 -di amine [3-(3-Dimethylamino-propyl)-5-(4-vitro-phenyl)-3H-thiazol157.02 -2-ylidene]-phenyl-amine [3-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)150.39 -propyl]-dimethyl-amine 2,3-Dimethyl-1H-indole-5-carboxylic acid 217.3 2-dimethylamino -ethyl ester N'-(3,4-Dinitro-5-pyridin-2-yl-thiophen-2-yl)-N,N-dimethyl282.12 -propane-1,3-diamine Cyclooctyl-dithiocarbamic acid 2-dimethylamino-ethyl185.31 ester (HCl) N-(2,6-Difluoro-phenyl)-C-dimethylamino-acetamide168:99 2-Acetylamino-3-(4-chloro-phenyl)-N-(3-dimethylamino142.31 -propyl)-acrylamide N-[2-[5-(4-Bromo-phenyl)-furan-2-yl]-1-(3-dimethylamino163.49 -propylcarbamoyl)-vinyl]-4-methyl-benzamide 2,6-Bis-(3-dimethylamino-propylamino)-3-vitro-benzonitrile167.75 N-[2-(2,4-Dichloro-phenoxy)-phenyl]-N'-(3-dimethylamino328.31 -propyl)-oxalamide 3,5-Dichloro-N-(3-dimethylamino-propyl)-2,6-dimethoxy193.93 -benzamide 2-Dimethylaminomethyl-3,4-dihydro-2H-naphthalen-1175.73 -one (HCl) 2-( { 1-[N-(3-Dimethylamino-propyl)-3-trifluoromethyl231.40 -phenyl]-methanimidoyl}-amino)-6-fluoro-benzoic acid 2,4-Dichloro-N-(3-dimethylamino-propyl)-N'-hydroxy212.83 -benzamidine 3-(3-Methyl-ureido)-4-oxo-3,4-dihydro-quinazoline-2305.22 -carboxylic acid (3-dimethylamino-propyl)-amide 5-Bromo-N-(3-dimethylamino-propyl)-2-hydroxy-benzamide258.28 N-(2,4-Dichloro-phenyl)-6-(2-dimethylamino-ethylsulfanyl)162.85 -4-trifluoromethyl-nicotinamide 1-(2,6-Dichloro-benzyl)-2-oxo-1,2-dihydro-pyridine-3149.44 -carboxylic acid (2-dimethylamino-ethyl)-amide 3-Amino-4-oxo-3,4-dihydro-quinazoline-2-carboxylic230.76 acid (3-dimethylamino-propyl)-amide

Claims (16)

1. Use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the activation of soluble guanylate cyclase wherein:
- R1 and R2 are the same or different and each represent a C1-C6 alkyl group, or R1 and R2 together form a C3-C6 alkylene group;
- Z is a C1-C4 alkylene group;
- P is a direct bond or a moiety -X-, -Y-, -W-, -XY-, -YW- or -XYW-, wherein:
- W is -O-, -S-, or -NR3, wherein R3 is hydrogen or C1-C6 alkyl;
- Y is a moiety -U-V- wherein V is a direct bond or a C1-C6 alkylene group and U is -CS-, -CO-, -S(O)2- or -C(=NR)-wherein R is hydrogen, hydroxy or C1-C6 alkyl;
- X is -O- or -NR6- wherein R6 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl or heteroaryl; and - R4 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, a group -R-A wherein R is -(C1-C6 alkyl)-, -(C2-C6 alkenyl)- or -(C2-C6 alkynyl)- and A is aryl, heteroaryl, carbocycyl or heterocyclyl, or R4 is a group -COR", -CO2R", -S(O)2R"
or -CONR'R" wherein R"is hydrogen, C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl and R" is is aryl, heteroaryl, carbocyclyl or heterocyclyl.
2. Use according to claim 1, wherein R1 and/or R2 are methyl.
3. Use according to claim 1 or 2, wherein Z is propylene.
4. Use according to any one of the preceding claims, wherein P is -XYW- or -YW-.
5. Use according to any one of the preceding claims, wherein W is -O- or -NR3-wherein R3 is as defined in claim 1.
6. Use according to any one of the preceding claims, wherein Y is -CO-.
7. Use according to any one of the preceding claims wherein X is -NH-.
8. Use according to any one of the preceding claims wherein R4 is C1-C6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, -(C1-C6 alkyl)-aryl, -(C1-C6 alkyl)-heteroaryl or -COR", -CO2R" or -CONR'R" wherein R' is hydrogen or C1-C6 alkyl and R" is an aryl, heteroaryl, carbocyclyl or heterocyclyl group.
9. Use according to any one of the preceding claims, wherein P is -XYW-, X is -NH- and R4 is phenyl, thienyl or pyrazolyl.
10. Use according to any one of claims 1 to 8, wherein P is -YW- and R4 is a chromonyl, pyrazolyl, thienyl, phenyl or indolyl group.
11. Use according to claim 1, wherein the compound of formula (I) is 1-(3-Dimethylamino-propyl)-3-(2-phenoxy-phenyl)-urea 1-[2-(4-Chloro-phenoxy)-pyridin-3-yl]-3-(3-dimethylaminopropyl)-urea 1-(3-Dimethylamino-propyl)-3-pyren-1-ylmethyl-urea 1-(3-Dimethylamino-propyl)-3-[(1R,2R)-5-phenyl-2-(1-phenyl-methanoyl)-cyclohexyl]-urea 1-(3-Dimethylamino-propyl)-3-[2-(4-phenoxy-phenyl)-ethyl]-urea 1-(3-Dimethylamino-propyl)-3-[3-methyl-5-(4-methyl-[1,2,3]thiadiazol-5-yl)-1-(4-trifluoromethoxy-phenyl)-1H-pyrazol-4-yl]-urea 2'-[3-(3-Dimethylamino-propyl)-ureido]-biphenyl-2-carboxylic acid (4-fluoro-phenyl)-amide N-(3-Chloro-4-methyl-phenyl)-4-[3-(3-dimethylamino-propyl)-ureido]-3-phenyl-butyramide 1-[4-(4-Chloro-phenylsulfanyl)-thiophen-3-yl]-3-(3-dimethylamino-propyl)-urea 1-[2-(3,4-Dimethoxy-phenyl)-6-methyl-quinolin-4-yl]-3-(4-dimethylamino-propyl)-urea 1-(6-Bromo-2-thiophen-3-yl-quinolin-4-yl)-3-(3-dimethylamino-propyl)-urea 1-[3-(4-Chloro-phenyl)-4-cyano-5-isobutylsulfanyl-thiophen-2-yl]-3-(3-dimethylamino-propyl)-urea 1-[6-(2,4-Dichloro-phenyl)-cyclohex-3-enyl]-3-(3-dimethylamino-propyl)-urea 1-(2-Benzylsulfanyl-phenyl)-3-(3-dimethylamino-propyl)-urea 2-{2-[3-(3-Dimethylamino-propyl)-ureido]-phenylsulfanyl}-N-phenyl-benzenesulfonamide 1-(3-Dimethylamino-propyl)-3-(2'-fluoro-biphenyl-4-yl)-urea N-(3,5-Dichloro-phenyl)-2-{3-[3-(3-dimethylamino-propyl)-ureido]-pyridin-2-ylsulfanyl}-acetamide 1-(3-Dimethylamino-propyl)-3-{2-[1-(1-trifluoromethyl-1,3,4,9-tetrahydro-b-carbolin-2-yl)-methanoyl]-phenyl}-urea 8-{2-[3-(3-Dimethylamino-propyl)-ureido]-phenylsulfanyl}-naphthalene-1-carboxylic acid methylamide 1-[1-(3,4-Dichloro-benzyl)-6-oxo-1,6-dihydro-pyridin-3-yl]-3-(3-dimethylamino-propyl)-urea 1-(3-Dimethylamino-propyl)-3-(3-oxo-1,2,3-triphenyl-propyl)-urea 1-[5-(4-Chloro-phenyl)-1-(3,4-dichloro-phenyl)-1H-pyrazol-3-yl]-3-(3-dimethylamino-propyl)-urea 1-{4-[4-(4-Chloro-phenyl)-thiazol-2-yl]-phenyl}-3-(3-dimethylamino-propyl)-urea 1-(3-Dimethylamino-propyl)-3-[5-(4-fluoro-phenyl)-thiophen-2-yl]-urea 1-[3-(4-tert-Butyl-benzyloxy)-thiophen-2-yl]-3-(3-dimethylamino-propyl)-urea 1-(3-Dimethylamino-propyl)-3-[4-(4-phenyl-thiazol-2-yl)-phenyl]-urea 1-[3-(3,4-Dichloro-benzylsulfanyl)-thiophen-2-yl]-3-(3-dimethylamino-propyl)-urea 1-[2-(5-Chloro-1-methyl-3-phenyl-1H-pyrazol-4-ylmethylsulfanyl)-phenyl]-3-(3-dimethylamino-propyl)-urea 1-[2-(4-Chloro-benzylsulfanyl)-3-methyl-4-oxo-3,4-dihydro-quinazolin-7-yl]-3-(3-dimethylamino-propyl)-urea 1-(3-Dimethylamino-propyl)-3-{4-[4-(4-methoxy-phenyl)-pyrimidin-2-ylsulfanylmethyl]-phenyl}-urea 1-(4-Bromophenyl)-3-(3-(1-pyrrolidinyl) propyl) urea 1-(4-Bromophenyl)-3-(3-dimethylamino propyl) urea 3-(4-Bromophenyl)-1-methyl-1-(3-dimethylamino propyl) urea 1-(3-Phenyl-5-methoxy phenyl)-3-(3-dimethylamino propyl) urea 3-(4-Chlorophenyl)-1-methyl-1-(3-dimethylamino propyl) urea 1-(3-Nitrophenyl)-1-benzyl-3-(3-dimethylamino propyl) urea 1-Benzyl-1-(4-methyl-3-pyridinyl)-3-(3-dimethylamino propyl) urea 1-Methyl-1-(3,5-bistrifluoromethylphenyl)-3-(3-dimethylaminopropyl)urea 1-(2-Phenacyl-4-chorophenyl)-1-methyl-3-(3-dimethylamino propyl) urea 1-(2-Chloro-4-trifluoromethylphenyl)-3-(3-dimethylaminopropyl) urea 1-(3-Fluoro-5-trifluoromethylphenyl)-3-(3-dimethylaminopropyl) urea 1-(3-N-tert-butoxycarbonyl-benzylamino)-3-(3-dimethylaminopropyl) urea N-(3-Dimethylamino-propyl)-2-[1-(4-fluorobenzoyl]-benzamide 2-[1-(4-Chlorobenzoyl]-N-(3-dimethylamino-propyl)-benzamide 5-(4-Chloro-phenyl)-1-phenyl-1H-pyrazole-3-carboxylic acid (3-dimethylamino-propyl)-amide 5-Chloro-3-phenyl-1H-indole-2-carboxylic acid (3-dimethylamino-propyl)-amide N-(3-Dimethylamino-propyl)-2-(2-phenylsulfamoyl-phenylsulfanyl)-benzamide 2-Benzylsulfanyl-N-(3-dimethylamino-propyl)-benzamide 6,8-Di-tert-butyl-4-oxo-4H-chromene-2-carboxylic acid (3-dimethylamino -propyl)-amide 3-(4-Chloro-phenyl)-4-cyano-5-isobutylsulfanyl-thiophene-2-carboxylic acid (3-dimethylamino-propyl)-amide 4-(4-Chloro-phenoxy)-N-(3-dimethylamino-propyl)-3-nitro-benzamide N-(3-Dimethylamino-propyl)-4-(4-phenyl-thiazol-2-yl)-benzamide 1-(3-Dimethylamino-propyl)-3-(2-phenoxyphenyl)-urea 1-[4-(4-Chloro-phenylsulfanyl)-thiophen-3-yl]-3-(3-dimethylamino-propyl) -urea 1-(3-Dimethylamino-propyl)-3-(2'-fluoro-biphenyl-4-yl)-urea N-(3-Dimethylamino-propyl)-2-[1-(4-fluorobenzoyl]-benzamide N-(3-Dimethylamino-propyl)-3-phenoxy-benzamide N-(3-Dimethylamino-propyl)-2-phenoxy-benzamide 2-(4-Chloro-phenoxy)-N-(3-dimethylamino-propyl)-nicotinamide 4'-n-Propyl-biphenyl-4-carboxylic acid (3-dimethylamino-propyl)-amide 2-[1-(4-Bromo-phenyl)-methanoyl]-cyclohexanecarboxylic acid (3-dimethylamino-propyl)-amide 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid (3-dimethylamino-propyl)-amide 2-[1-(4-Chlorobenzoyl]-N-(3-dimethylamino-propyl)-benzamide 2-Phenyl-quinoline-4-carboxylic acid (3-dimethylamino-propyl)-amide 2-[1-(4-Chloro-3-nitrobenzoyl)]-N-(3-dimethylamino-propyl)-benzamide N-(3-Dimethylamino-propyl)-2-pyren-1-yl-acetamide N-(3-Dimethylamino-propyl)-2-[1-(3-methyl-benzo[b]thiophen-2-yl)-methanoyl]-benzamide 4-Chloro-N-(3-dimethylamino-propyl)-2-phenoxy-benzamide N-(3-Dimethylamino-propyl)-3-(4-phenoxy-phenyl)-propionamide N-(3-Dimethylamino-propyl)-2-[1-(1-trifluoromethyl-1,3,4,9-tetrahydro-b-carbolin-2-yl)-methanoyl]-benzamide 1-(4-Chloro-phenyl)-2,5-dimethyl-1-pyrrole-3-carboxylic acid (3-dimethylamino-propyl)-amide 2-{1-[(3-Dimethylamino-propylcarbamoyl)-methyl]-cyclopentyl}-N-(4-trifluoromethoxy-phenyl)-acetamide 8-[2-(3-Dimethylamino-propylcarbamoyl)-phenylsulfanyl]-naphthalene-1-carboxylic acid methylamide 3-Methyl-5-(4-methyl-[1,2,3]thiadiazol-5-yl)-1-(4-trifluoromethoxy-phenyl)-1H-pyrazole-4-carboxylic acid (3-dimethylamino-propyl)-amide 6,8-Di-tert-butyl-4-oxo-4H-chromene-2-carboxylic acid (3-dimethylamino-propyl)-amide 2-(Furan-2-yl)-quinoline-4-carboxylic acid (3-dimethylamino-propyl)-amide Biphenyl-2,2'-dicarboxylic acid 2'-[(3-dimethylamino-propyl)-amide]-2-[(4-fluoro-phenyl)-amide]
3-Phenyl-pentanedioic acid (3-chloro-4-methyl-phenyl)-amide (3-dimethylamino-propyl)-amide 2-(3,4-Dimethoxy-phenyl)-6-methyl-quinoline-4-carboxylic acid (3-dimethylamino-propyl)-amide 6-Bromo-(2-thiophen-3-yl)-quinoline-4-carboxylic acid (3-dimethylamino-propyl)-amide 3-(4-Chloro-phenyl)-4-cyano-5-isobutylsulfanyl-thiophene-2-carboxylic acid (3-dimethylamino-propyl)-amide 4-(4-Chloro-phenoxy)-N-(3-dimethylamino-propyl)-3-nitro-benzamide 6-(2,4-Dichloro-phenyl)-cyclohex-3-ene carboxylic acid (3-dimethylamino-propyl)-amide N-(3-Dimethylamino-propyl)-2-(2-phenylsulfamoyl-phenylsulfanyl)-benzamide 2'-Fluoro-[1,1'-biphenyl]-4-carboxylic acid (3-dimethylamino-propyl)-amide 2-Benzylsulfanyl-N-(3-dimethylamino-propyl)-benzamide Pyrazine-2,3-dicarboxylic acid 2-[(3-dimethylamino-propyl)-amide] 3-[(5,6,7,8-tetrahydro-naphthalen-1-yl)-amide]
2-[(3,5-Dichloro-phenylcarbamoyl)-methylsulfanyl]-N-(3-dimethylamino-propyl)-nicotinamide 2-(3-Trifluoromethyl-phenyl)-thiazole-4-carboxylic acid (3-dimethylamino-propyl)-amide 2-(4-Chloro-phenyl)-thiazole-4-carboxylic acid (3-dimethylamino-propyl)-amide 5-Chloro-1-(2,4-dichloro-benzyl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid (3-dimethylamino-propyl)-amide 1-(2,4-Dichloro-benzyl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid (3-dimethylamino-propyl)-amide 5-Chloro-1-(3,4-dichloro-benzyl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid (3-dimethylamino-propyl)-amide 1-(3,4-Dichloro-benzyl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid (3-dimethylamino-propyl)-amide 5-Chloro-1-(2,6-dichloro-benzyl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid (3-dimethylamino-propyl)-amide 1,1-Dimethyl-indan-4-carboxylic acid (3-dimethylamino-propyl)-amide N-(3-Dimethylamino-propyl)-2-[1-(4-ethyl-phenyl)-methanoyl]-benzamide N-(3-Dimethylamino-propyl)-3-(2,4,5-trimethyl-phenyl)-butyramide 2-[3-(3,4-Dichloro-phenyl)-ureido]-N-(3-dimethylamino-propyl)-benzamide N-(3-Dimethylamino-propyl)-4-oxo-2,3,4-triphenyl-butyramide 5-(4-Chloro-phenylsulfanyl)-[1,2,3]thiadiazole-4-carboxylic acid (3-dimethylamino-propyl)-amide 2-(3-Chloro-5-trifluoromethyl-pyridin-2-ylsulfanyl)-3-methyl-3H-imidazole-4-carboxylic acid (3-dimethylamino-propyl)-amide 2-(2-Chloro-4-trifluoromethyl-phenyl)-[1,3]-thiazole-4-carboxylic acid (3-dimethylamino-propyl)-amide 2-(2,3-Dihydro-1-benzofuran-5-yl)-1,3-thiazole-4-carboxylic acid (3-dimethylamino-propyl)-amide 2-(2,3-Dichloro-phenyl)-1,3-thiazole-4-carboxylic acid (3-dimethylamino-propyl)-amide 4-[4-(4-Chloro-phenyl)-thiazol-2-yl]-N-(3-dimethylamino-propyl)-benzamide 5-(4-Fluoro-phenyl)-thiophene-2-carboxylic acid (3-dimethylamino-propyl)-amide 4-Methyl-2-(3-trifluoromethyl-phenyl)-thiazole-5-carboxylic acid (3-dimethylamino-propyl)-amide 3-(4-tert-Butyl-benzyloxy)-thiophene-2-carboxylic acid (3-dimethylamino-propyl)-amide 4-Oxo-3-(3-trifluoromethyl-phenyl)-3,4-dihydro-phthalazine-1-carboxylic acid (3-dimethylamino-propyl)-amide 2-(4-Chloro-phenyl)-N-(3-dimethylamino-propyl)-4-oxo-4-phenyl-butyramide 5-(4-Chloro-phenyl)-1-phenyl-1H pyrazole-3-carboxylic acid (3-dimethylamino-propyl)-amide N-(3-Dimethylamino-propyl)-4-(4-phenyl-thiazol-2-yl)-benzamide 1-(2,4,5-Trichloro-phenylsulfonyl)-pyrrolidine-2-carboxylic acid (3-dimethylamino-propyl)-amide 3-(3,4-Dichloro-benzylsulfanyl)-thiophene-2-carboxylic acid (3-dimethylamino-propyl)-amide 5-Chloro-3-phenyl-1H-indole-2-carboxylic acid (3-dimethylamino-propyl)-amide N-(3-Dimethylamino-propyl)-2-[1-(4-fluoro-benzyl)-1H-indol-3-yl]-acetamide 2-Phenyl-imidazo[1,2-a]pyridine-3-carboxylic acid (3-dimethylamino-propyl)-amide N-(3-Dimethylamino-propyl)-2-(7-ethyl-1H-indol-3-yl)-4-oxo-4-phenyl-butyramide Phenyl-trifluoromethyl-thieno[3,2-b]pyridine-2-carboxylic acid (3-dimethylamino-propyl)-amide 3-(4-Nitro-3-trifluoromethyl-phenoxy)-thiophene-2-carboxylic acid (3-dimethylamino-propyl)-amide 2-(5-Chloro-1-methyl-3-phenyl-1H-pyrazol-4-ylmethylsulfanyl)-N-(3-dimethylamino-propyl)-benzamide 2-(4-Chloro-benzylsulfanyl)-3-methyl-4-oxo-3,4-dihydro-quinazoline-7 -carboxylic acid (3-dimethylamino-propyl)-amide N-(3-Dimethylamino-propyl)-4-[4-(4-methoxy-phenyl)-pyrimidin-2 -ylsulfanylmethyl]-benzamide 1-(4-chlorobenzyl)-3-(2-N,N-dimethylethylamido)-6-pyridone 1-(2,6-dichlorobenzyl)-3-(3-N,N-dimethylpropylamido)-6-pyridone 1-(3-trifluoromethylbenzyl)-3-(2-N,N-dimethylethylamido)-2-pyridone 1-(2,6-dichlorobenzyl)-3-(2-N,N-dimethylethylamido)-2-pyridone 1-(3,4-dichlorobenzyl)-3-(N-[2,N,N-dimethylaminoethylamido])-2-pyridone 1-(2,6-dichlorobenzyl)-3-(N-[2-N,N-dimethylaminoethylamido])-6-pyridone 5-chloro-1-(3,4-dichlorobenzyl)-3-(2-N,N-dimethylaminoethylamido)-6 -pyridone 5-chloro-3-(2-N,N-dimethylaminoethylamido)-1-(3-trifluoromethylbenzyl)-6-pyridone 5-chloro-1-(3,4-dichlorobenzyl)-3-N-(2-[N',N'-dimethylaminoethylamido])-2-pyridone 5-chloro-1-(4-chlorobenzyl)-3-N-(2-(N',N'-dimethylamino)ethyl)amido-2-pyridone 5-chloro-1-(3-trifluoromethylbenzyl)-3-N-(2-(N',N'-dimethylamino)ethyl) amido-2-pyridone 1-benzyl-5-chloro-3-N-(2-[N',N'-dimethylamino]ethyl)carboxamido-6-pyridone 5-chloro-1-(4-chlorobenzyl)-3-N-(2-[N',N'-dimethylamino]ethyl)carboxamido -6-pyridone 4-(2,4-dichlorobenzoyl)pyrrole-2-N-dimethylaminopropylcarboxamide 4-[(N-[3-(N',N'-dimethylaminopropyl)]carboxamido]-2-phenylthiazole 4-(N-(3-N',N'-dimethylaminopropyl)carboxamido)-2-(4-pyridinyl)thiazole 2-[4-(N-[3-N',N'-dimethylaminopropyl]carboxamido)phenyl-4-(3-trifluoromethylphenyl)]thiazole 4-(4-chlorophenyl)-2-(4-[3-N',N'-dimethylaminopropyl]carboxamido)phenyl) thiazole 1-(3,5-bis(trifluoromethyl)benzyl)-3-[N-(2-dimethylaminoethyl) carboxamido]-2[1H]-pyridone N-(3-dimethylaminopropyl)-4-(3-chloro-5-trifluoromethyl-2-pyridyloxy) phenylsulfonamide N1-[3-(dimethylamino)propyl]-3-[3-chloro-5-(trifluoromethyl)-2-pyridyl]
propanamide 3-(N-(2-dimethylaminoethyl)carboxamido]-1-(4-trifluoromethylbenzyl))-2 [1H]-pyridone 1-ethyl-3-(3-dimethylaminopropyl)urea 1-(3-(dimethylamino)-propyl)-3-phenylurea N1-[2-(2,4-dichlorophenoxy)phenyl]-N2-[3-(dimethylamino)propyl]
ethanediamide N4-[3-(dimethylamino)propyl]-3-(2,6-dichlorophenyl)-5-methylisoxazole-4-c arboxamide N-[[3-(2,6-dichlorophenyl)-5-methylisoxazol-4-yl]carbonyl]-N'-[3-(dimethyla mino)propyl]urea N-(4-chlorophenyl)-N'-[3-dimethylaminopropyl]urea N-(3,5-Dichloro-phenyl)-3-(3-dimethylamino-propylamino)-propionamide [3-(2-Ethyl-6-methyl-pyridin-3-yloxy)-propyl]-dimethyl-amine 8-(3-Dimethylamino-propoxy)-1,3,7-trimethyl-3,7-dihydro-purine-2,6-dione 2-(3-Dimethylamino-propylamino)-isophthalonitrile Dimethylamino-(3-methyl-benzo[b]thiophen-2-yl)-propan-1-one (HCl) N-Benzo[1,3]dioxol-5-ylmethyl-N,N-dimethyl-propane-1,3-diamine N,N-Dimethyl-N-(5-nitro-quinolin-8-yl)-propane-1,3-diamine 1-(4-Chloro-phenyl)-3-(3-dimethylamino-propyl)-urea 2-Amino-N-(3-dimethylamino-propyl)-benzamide 3-Phenyl-acrylic acid 3-dimethylamino-propyl ester 3,5-Dinitro-benzoic acid 2-dimethylamino-ethyl ester [4-(4-Bromo-phenyl)-3-(3-dimethylamino-propyl)-3H-thiazol-2-ylidene]-phenyl-amine 3-Methyl-benzofuran-2-carboxylic acid dimethylamino-dimethyl-propyl ester N'-(2-Chloro-4-nitro-phenyl)-N,N-dimethyl-propane-1,3-diamine [3-(3-Dimethylamino-propyl)-5-(4-nitro-phenyl)-3H-thiazol-2-ylidene]-phenyl-amine [3-(10,11-Dihydro-dibenzo [a,d]cyclohepten-5-ylidene)-propyl]-dimethyl-amine 2,3-Dimethyl-1H-indole-5-carboxylic acid 2-dimethylamino-ethyl ester N'-(3,4-Dinitro-5-pyridin-2-yl-thiophen-2-yl)-N,N-dimethyl-propane-1,3-diamine Cyclooctyl-dithiocarbamic acid 2-dimethylamino-ethyl ester (HCl) N-(2,6-Difluoro-phenyl)-C-dimethylamino-acetamide 2-Acetylamino-3-(4-chloro-phenyl)-N-(3-dimethylamino-propyl)-acrylamide N-[2-[5-(4-Bromo-phenyl)-furan-2-yl]-1-(3-dimethylamino-propyl carbamoyl)-vinyl]-4-methyl-benzamide 2,6-Bis-(3-dimethylamino-propylamino)-3-nitro-benzonitrile N-[2-(2,4-Dichloro-phenoxy)-phenyl]-N'-(3-dimethylamino-propyl)-oxalamide 3,5-Dichloro-N-(3-dimethylamino-propyl)-2,6-dimethoxy-benzamide 2-Dimethylaminomethyl-3,4-dihydro-2H-naphthalen-1-one (HCl) 2-({1-[N-(3-Dimethylamino-propyl)-3-trifluoromethyl-phenyl]-methanimidoyl}-amino)-6-fluoro-benzoic acid 2,4-Dichloro-N-(3-dimethylamino-propyl)-N'-hydroxy-benzamidine 3-(3-Methyl-ureido)-4-oxo-3,4-dihydro-quinazoline-2-carboxylic acid (3-dimethylamino-propyl)-amide 5-Bromo-N-(3-dimethylamino-propyl)-2-hydroxy-benzamide N-(2,4-Dichloro-phenyl)-6-(2-dimethylamino-ethylsulfanyl)-4-trifluoromethyl-nicotinamide 1-(2,6-Dichloro-benzyl)-2-oxo-1,2-dihydro-pyridine-3-carboxylic acid (2-dimethylamino-ethyl)-amide 3-Amino-4-oxo-3,4-dihydro-quinazoline-2-carboxylic acid (3-dimethylamino-propyl)-amide
12. Use according to any one of the preceding claims, wherein the medicament is for use as a vasodilator or to inhibit platelet aggregation.
13. Use according to claim 12, wherein the medicament is for use in the treatment or prevention of a peripheral vascular disease, glaucoma, age-related macular degeneration, preeclampsia, Raynaud's Syndrome, stroke or erectile dysfunction.
14. A method of treating a patient in need of an activator of soluble guanylate cyclase, which method comprises administering to said patient an effective amount of a compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof.
15. A compound of the formula (I), as defined in any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, for use in the treatment of the human or animal body by therapy.
16. A compound of the formula (I), as defined in any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, excluding the following compounds:
2-Benzylsulfanyl-N-(3-dimethylamino-propyl)-benzamide N-(3-Dimethylamino-propyl)-3-phenoxy-benzamide 1-(4-chlorobenzyl)-3-(2-N,N-dimethylethylamido)-6-pyridone 1-(2,6-dichlorobenzyl)-3-(3-N,N-dimethylpropylamido)-6-pyridone 1-(3-trifluoromethylbenzyl)-3-(2-N,N-dimethylethylamido)-2-pyridone 1-(2,6-dichlorobenzyl)-3-(2-N,N-dimethylethylamido)-2-pyridone 1-(3,4-dichlorobenzyl)-3-(N-[2,N,N-dimethylaminoethylamido])-2-pyridone 1-(2,6-dichlorobenzyl)-3-(N-[2-N,N-dimethylaminoethylamido])-6-pyridone 5-chloro-1-(3,4-dichlorobenzyl)-3-(2-N,N-dimethylaminoethylamido)-6-pyridone 5-chloro-3-(2-N,N-dimethylaminoethylamido)-1-(3-trifluoromethylbenzyl)-6-pyridone 5-chloro-1-(3,4-dichlorobenzyl)-3-N-(2-[N',N'-dimethylaminoethylamido])-2-pyridone 5-chloro-1-(4-chlorobenzyl)-3-N-(2-(N',N'-dimethylamino)ethyl)amido-2-pyridone 5-chloro-1-(3-trifluoromethylbenzyl)-3-N-(2-(N',N'-dimethylamino)ethyl) amido-2-pyridone 1-benzyl-5-chloro-3-N-(2-[N',N'-dimethylamino]ethyl)carboxamido-6-pyridone 5-chloro-1-(4-chlorobenzyl)-3-N-(2-[N',N'-dimethylamino]ethyl) carboxamido-6-pyridone 4-(2,4-dichlorobenzoyl)pyrrole-2-N-dimethylaminopropylcarboxamide 4-[(N-[3-(N',N'-dimethylaminopropyl)]carboxamido]-2-phenylthiazole 4-(N-(3-N',N'-dimethylaminopropyl)carboxamido)-2-(4-pyridinyl)thiazole 2-[4-(N-[3-N',N'-dimethylaminopropyl]carboxamido)phenyl-4-(3-trifluoromethylphenyl]thiazole 4-(4-chlorophenyl)-2-(4-[3-N',N'-dimethylaminopropyl]carboxamido)phenyl) thiazole 1-(3,5-bis(trofluoromethyl)benzyl)-3-[N-(2-dimethylaminoethyl) carboxamido]-2[1H]-pyridone N-(3-dimethylaminopropyl)-4-(3-chloro-5-trifluoromethyl-2-pyridyloxy) phenylsulfonamide N1-[3-(dimethylamino)propyl]-3-[3-chloro-5-(trifluoromethyl)-2-pyridyl]
propanamide 3-(N-(2-dimethylaminoethyl)carboxamido]-1-(4-trifluoromethylbenzyl))-2 [1H]-pyridone 1-ethyl-3-(3-dimethylaminopropyl)urea 1-(3-(dimethylamino)-propyl)-3-phenylurea N1-[2-(2,4-dichlorophenoxy)phenyl]-N2-[3-(dimethylamino)propyl]
ethanediamide N4-[3-(dimethylamino)propyl]-3-(2,6-dichlorophenyl)-5-methylisoxazole-4-c arboxamide N-[[3-(2,6-dichlorophenyl)-5-methylisoxazol-4-yl]carbonyl]-N'-[3-(dimethylamino)propyl]urea N-(4-chlorophenyl)-N'-[3-dimethylaminopropyl]urea N-(3,5-Dichloro-phenyl)-3-(3-dimethylamino-propylamino)-propionamide [3-(2-Ethyl-6-methyl-pyridin-3-yloxy)-propyl]-dimethyl-amine 8-(3-Dimethylamino-propoxy)-1,3,7-trimethyl-3,7-dihydro-purine-2,6-dione 2-(3-Dimethylamino-propylamino)-isophthalonitrile Dimethylamino-(3-methyl-benzo[b]thiophen-2-yl)-propan-1-one (HCl) N-Benzo[1,3]dioxol-5-ylmethyl-N,N-dimethyl-propane-1,3-diamine N,N-Dimethyl-N-(5-vitro-quinolin-8-yl)-propane-1,3-diamine 1-(4-Chloro-phenyl)-3-(3-dimethylamino-propyl)-urea 2-Amino-N-(3-dimethylamino-propyl)-benzamide 3-Phenyl-acrylic acid 3-dimethylamino-propyl ester 3,5-Dinitro-benzoic acid 2-dimethylamino-ethyl ester [4-(4-Bromo-phenyl)-3-(3-dimethylamino-propyl)-3H-thiazol-2-ylidene]-phenyl-amine 3-Methyl-benzofuran-2-carboxylic acid dimethylamino-dimethyl-propyl ester N'-(2-Chloro-4-vitro-phenyl)-N,N-dimethyl-propane-1,3-diamine [3-(3-Dimethylamino-propyl)-5-(4-nitro-phenyl)-3H-thiazol-2-ylidene]-phenyl-amine [3-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-dimethyl-amine 2,3-Dimethyl-1H-indole-5-carboxylic acid 2-dimethylamino-ethyl ester N'-(3,4-Dinitro-5-pyridin-2-yl-thiophen-2-yl)-N,N-dimethyl-propane-1,3-diamine Cyclooctyl-dithiocarbamic acid 2-dimethylamino-ethyl ester (HCl) N-(2,6-Difluoro-phenyl)-C-dimethylamino-acetamide 2-Acetylamino-3-(4-chloro-phenyl)-N-(3-dimethylamino-propyl)-acrylamide N-[2-[5-(4-Bromo-phenyl)-furan-2-yl]-1-(3-dimethylamino-propylcarbamoyl)-vinyl]-4-methyl-benzamide 2,6-Bis-(3-dimethylamino-propylamino)-3-nitro-benzonitrile N-[2-(2,4-Dichloro-phenoxy)-phenyl]-N'-(3-dimethylamino-propyl)-oxalamide 3,5-Dichloro-N-(3-dimethylamino-propyl)-2,6-dimethoxy-benzamide 2-Dimethylaminomethyl-3,4-dihydro-2H-naphthalen-1-one (HCl) 2-({1-[N-(3-Dimethylamino-propyl)-3-trifluoromethyl-phenyl]-methanimidoyl]-amino)-6-fluoro-benzoic acid 2,4-Dichloro-N-(3-dimethylamino-propyl)-N'-hydroxy-benzamidine 3-(3-Methyl-ureido)-4-oxo-3,4-dihydro-quinazoline-2-carboxylic acid (3-dimethylamino-propyl)-amide 5-Bromo-N-(3-dimethylamino-propyl)-2-hydroxy-benzamide N-(2,4-Dichloro-phenyl)-6-(2-dimethylamino-ethylsulfanyl)-4-trifluoromethyl-nicotinamide 1-(2,6-Dichloro-benzyl)-2-oxo-1,2-dihydro-pyridine-3-carboxylic acid (2-dimethylamino-ethyl)-amide 3-Amino-4-oxo-3,4-dihydro-quinazoline-2-carboxylic acid (3-dimethylamino-propyl)-amide
CA002389773A 1999-11-05 2000-11-06 Activators of soluble guanylate cyclase Abandoned CA2389773A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9926286.7 1999-11-05
GBGB9926286.7A GB9926286D0 (en) 1999-11-05 1999-11-05 Activators of soluble guanylate cyclase
US20138200P 2000-05-02 2000-05-02
US60/201,382 2000-05-02
PCT/GB2000/004249 WO2001032604A1 (en) 1999-11-05 2000-11-06 Activators of soluble guanylate cyclase

Publications (1)

Publication Number Publication Date
CA2389773A1 true CA2389773A1 (en) 2001-05-10

Family

ID=26316060

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002389773A Abandoned CA2389773A1 (en) 1999-11-05 2000-11-06 Activators of soluble guanylate cyclase

Country Status (5)

Country Link
EP (1) EP1237849A1 (en)
JP (1) JP2003513064A (en)
AU (1) AU1161601A (en)
CA (1) CA2389773A1 (en)
WO (1) WO2001032604A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014084312A1 (en) * 2012-11-30 2014-06-05 アステラス製薬株式会社 Imidazopyridine compound

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001266345B2 (en) 2000-06-30 2006-03-02 Sumitomo Dainippon Pharma Co., Ltd. Five-membered-ring compound
JP2003081937A (en) * 2001-09-07 2003-03-19 Bayer Ag Benzenesulfonamide derivative
DK1482931T3 (en) 2002-03-05 2011-12-19 Transtech Pharma Inc Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with RAGE
DE10216145A1 (en) * 2002-04-12 2003-10-23 Bayer Ag Use of stimulators of soluble guanylate cyclase to produce a medicament for treating glaucoma
US20040121994A1 (en) * 2002-12-20 2004-06-24 Anderson Steven N. Novel amides that activate soluble guanylate cyclase
CN1802159B (en) 2003-03-24 2013-04-24 阿克西金药品公司 2-phenoxy- and 2-phenylsulfomamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders
JP2007084437A (en) * 2003-12-26 2007-04-05 Dai Ichi Seiyaku Co Ltd Aminoalkylpyrazole derivative
ATE552251T1 (en) * 2004-01-09 2012-04-15 Lilly Co Eli THIOPHENE AND FURAN COMPOUNDS
US20070179137A1 (en) * 2004-03-24 2007-08-02 Rimonyx Pharmaceuticals Ltd. Screening of anti-viral drugs and pharmaceuticals composition containing thiazolidinone derivatives
WO2006089076A2 (en) * 2005-02-18 2006-08-24 Neurogen Corporation Thiazole amides, imidazole amides and related analogues
DE102005011534A1 (en) * 2005-03-10 2006-09-21 Merck Patent Gmbh Chromen-4-one derivatives
DE102005047945A1 (en) * 2005-07-16 2007-01-18 Bayer Healthcare Ag Use of soluble guanylate cyclase activators for the treatment of Raynaud's phenomena
JP2009523748A (en) * 2006-01-18 2009-06-25 シエナ ビオテク ソシエタ ペル アチオニ Modulators of α7 nicotinic acetylcholine receptors and their use in therapy
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
WO2009032249A1 (en) * 2007-09-06 2009-03-12 Merck & Co., Inc. Soluble guanylate cyclase activators
DE102008018675A1 (en) * 2008-04-14 2009-10-15 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclic substituted carboxylic acid derivatives and their use
JP2011521941A (en) * 2008-05-30 2011-07-28 ミトロジクス ANT-ligand molecules and biological applications
US8580833B2 (en) 2009-09-30 2013-11-12 Transtech Pharma, Inc. Substituted imidazole derivatives and methods of use thereof
MX336559B (en) 2010-03-17 2016-01-25 Axikin Pharmaceuticals Inc Arylsulfonamide ccr3 antagonists.
CN102250006B (en) * 2011-05-12 2014-03-05 范如霖 3-pyrazole carboxylic acid amide compounds, preparation method thereof and application thereof in preparation of medicament serving as CB1 receptor inhibitor
CN103608347B (en) 2011-05-30 2016-04-27 安斯泰来制药株式会社 Imidazopyridine
WO2016023885A1 (en) * 2014-08-14 2016-02-18 Bayer Pharma Aktiengesellschaft Substituted quinoline-4-carboxamides and use thereof
CN106831494B (en) * 2017-03-14 2018-04-17 青岛科技大学 A kind of mebenil base hexichol carbamide compounds and application thereof
EP4378932A1 (en) * 2022-11-30 2024-06-05 Universität Bern Novel cd93 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE890958C (en) * 1940-06-11 1953-09-24 Bayer Ag Process for the preparation of sulfonamide compounds
US2553093A (en) * 1947-11-04 1951-05-15 Rhone Poulenc Sa Aminoalkylethanesulfonamide
US2628224A (en) * 1951-01-16 1953-02-10 Du Pont Vinyl dialkylaminohydrocarbonamides
DE1020636B (en) * 1954-11-12 1957-12-12 Geigy Ag J R Process for the preparation of 3-phenyl-7-acylamino-coumarins
US2777853A (en) * 1955-09-06 1957-01-15 Hoffmann La Roche Mercapto benzothiazole compounds
US3170955A (en) * 1958-04-25 1965-02-23 Abbott Lab Amino and halogen substituted-n-diloweralkylamino-alkyl-benzamides
DE1156080B (en) * 1959-02-07 1963-10-24 Laeaeketehdas Orion Oy Process for the production of aromatic acid amides substituted in the two ortho positions
FR1586112A (en) * 1968-05-27 1970-02-13
IE47458B1 (en) * 1977-11-07 1984-03-21 Leo Pharm Prod Ltd Quinolylguanidine derivatives
DE4038128A1 (en) * 1990-11-27 1992-06-04 Schering Ag 8-EN-19, 11 (BETA) BRIDGED STEROIDS, THEIR PRODUCTION AND THEIR PHARMACEUTICAL PREPARATIONS CONTAINING THEM
FR2670780B1 (en) * 1990-12-20 1993-07-09 Synthelabo DERIVATIVES OF 4- (ACYLAMINO) BENZOPYRANS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION.
DE19744026A1 (en) * 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazole derivatives, their preparation and their use in medicinal products
DE19756388A1 (en) * 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh New 2-aryl-4-amino-6,7-di:methoxy-quinazoline derivatives useful as guanylate cyclase activators for treating cardiovascular diseases, etc.
DE19836697A1 (en) * 1998-08-13 2000-02-17 Hoechst Marion Roussel De Gmbh New substituted 4-amino-2-aryl-pyrimidines, are soluble guanylate cyclase activators useful e.g. for treating atherosclerosis, hypertension, angina pectoris, thrombosis, asthma or diabetes
GB9824310D0 (en) * 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014084312A1 (en) * 2012-11-30 2014-06-05 アステラス製薬株式会社 Imidazopyridine compound

Also Published As

Publication number Publication date
AU1161601A (en) 2001-05-14
EP1237849A1 (en) 2002-09-11
JP2003513064A (en) 2003-04-08
WO2001032604A1 (en) 2001-05-10

Similar Documents

Publication Publication Date Title
CA2389773A1 (en) Activators of soluble guanylate cyclase
JP6046154B2 (en) (Hetero) arylcyclopropylamine compounds as LSD1 inhibitors
CN100522937C (en) Anthranilic acid amides, method for the production thereof, their use as antiarrhythmia agents, and pharmaceutical preparations thereof
TWI286550B (en) Benzophenones as inhibitors of reverse transcriptase
AU2009273932B2 (en) Beta-and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
RU2463292C2 (en) 4-substituted phenoxyphenylacetic acid derivatives
JP4927304B2 (en) Pharmaceutically active sulfonamide derivatives carrying lipophilic and ionizable components as inhibitors of protein Jun-kinase
TWI242005B (en) Ortho, ortho-substituted nitrogen-containing bisaryl compounds, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
US6482822B1 (en) N-(iminomethyl)amines derivatives, their preparation, their use as medicines and compositions containing them
JP5043645B2 (en) carboxylic acid
JP4644714B2 (en) New cyclohexane derivatives
US6727239B1 (en) Derivatives of 2-aminopyridines, their use as medicaments and pharmaceutical compositions containing them
AU2008205047A2 (en) 6-aminoisoquinoline compounds useful as kinase modulators
NZ555971A (en) Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
NO324792B1 (en) Pharmaceutically active sulfonamide derivatives
US20090005426A1 (en) Pharmaceutically active sulfonyl hydrazide derivatives
NZ583689A (en) F1f0-atpase inhibitors and related methods
WO2019178324A1 (en) Amino-benzoisothiazole and amino-benzoisothiadiazole amide compounds
AU2004261400A1 (en) Alkynyl aryl carboxamides
CN102170882B (en) Compositions and methods of treating amyloid disease
KR102132744B1 (en) Imidazopyridine derivatives useful in treating diabetes
JPH11240832A (en) Amide or amine derivative
NZ244029A (en) Alkylamide tetrazole acat inhibitors
JP2020506226A (en) Amide compounds and uses thereof
JP2004513936A (en) Glucagon antagonist / inverse agonist

Legal Events

Date Code Title Description
FZDE Dead